(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 November 2013 (07.11.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/164404 A1

(51) International Patent Classification:
B01D 15/38 (2006.01) *C12N 15/62* (2006.01)
C07K 14/435 (2006.01) *C07K 14/00* (2006.01)

(21) International Application Number:
PCT/EP2013/059145

(22) International Filing Date:
2 May 2013 (02.05.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
12166392.6 2 May 2012 (02.05.2012) EP

(71) Applicants: **SPIBER TECHNOLOGIES AB** [SE/SE]; Husargatan 3, Box 575, S-751 23 Uppsala (SE). **IMMUNOVIA AB** [SE/SE]; Medicon Village, S-223 81 Lund (SE).

(72) Inventors: **HEDHAMMAR, My**; Odengatan 40, S-113 51 Stockholm (SE). **JOHANSSON, Jan**; Renstiernas Gata 40, S-116 31 Stockholm (SE). **RISING, Anna**; Doppingvägen 12, S-756 51 Uppsala (SE). **NYGREN, Per-Åke**; Singelgränd 36, S-178 40 Ekerö (SE).

(74) Agent: **HENRIKSSON, Mikael**; Awapatent Ab, P.O. Box 45086, S-104 30 Stockholm (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: SPIDER SILK FUSION PROTEIN STRUCTURES INCORPORATING IMMUNOGLOBULIN FRAGMENTS AS AFFINITY LIGANDS



Fig 6

(57) Abstract: A recombinant fusion protein comprising the moieties Band CT, and optionally REP, wherein Bis comprising at least one immunoglobulin fragment, which provides the capacity of selective interaction with anorganic target;CTis a moiety of from 70 to 120 amino acid residues and is derived from the C-terminal fragment of a spider silk protein; and REPis a moiety of from 70 to 300 amino acid residues and is derived from the repetitive fragment of a spider silk protein.

WO 2013/164404 A1

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

SPIDER SILK FUSION PROTEIN STRUCTURES INCORPORATING IMMUNOGLOBULIN FRAGMENTS AS AFFINITY LIGANDS

Technical field of the invention

The present invention relates to the field of recombinant fusion proteins, and more specifically to novel fusion proteins comprising moieties derived from spider silk proteins (spidroins). The present invention provides methods for providing a protein structure which is a polymer comprising a recombinant fusion protein, which is comprising moieties derived from spidroins. There is also provided novel protein structures for binding to an organic target.

Background to the invention

In applied protein chemistry, it is a common problem how to formulate or present a biologically active peptide or protein to the relevant site of activity, typically an organic target, such as a nucleic acid, a protein, a complex of proteins, or a complex of a protein(s) and/or lipids and/or carbohydrates and/or a nucleic acid(s). The simplest solution is simply to provide an aqueous solution of the biologically active peptide or protein. Many applications do however require some further means to achieve the desired goal. For instance, the peptides/proteins may be associated with a lipid mixture or chemically immobilized to a support structure.

Applications for peptides/proteins immobilized to a support structure include preparative and analytical separation procedures, such as bioprocesses, chromatography, cell capture and culture, active filters, and diagnostics. Structures based on extracellular matrix proteins, e.g. collagen, are disclosed in EP 704 532 and EP 985 732.

It has also been suggested to use spider silk proteins in a supporting structure. Spider silks are nature´s high-performance polymers, obtaining extraordinary toughness and extensibility due to a combination of strength and elasticity. Spiders have up to seven different glands which produce a variety of silk types with different mechanical properties and functions.

Dragline silk, produced by the major ampullate gland, is the toughest fiber. It consists of two main polypeptides, mostly referred to as major ampullate spidroin (MaSp) 1 and 2, but e.g. as ADF-3 and ADF-4 in *Araneus diadematus*. These proteins have molecular masses in the range of 200-720 kDa. Spider dragline silk proteins, or MaSps, have a tripartite composition; a non-repetitive N-terminal domain, a central repetitive region comprised of many iterated poly-Ala/Gly segments, and a non-repetitive C-terminal domain. It is generally believed that the repetitive region forms intermolecular contacts in the silk fibers, while the precise functions of the terminal domains are less clear. It is also believed that in association with fiber formation, the repetitive region undergoes a structural conversion from random coil and α-helical conformation to β-sheet structure. The C-terminal region of spidroins is generally conserved between spider species and silk types.

W0 07/078239 and Stark, M. *et al.*, Biomacromolecules 8: 1695-1701, (2007) disclose a miniature spider silk protein consisting of a repetitive fragment with a high content of Ala and Gly and a C-terminal fragment of a protein, as well as soluble fusion proteins comprising the spider silk protein. Fibers of the spider silk protein are obtained spontaneously upon liberation of the spider silk protein from its fusion partner.

Rising, A. *et al.*, CMLS 68(2): 169-184 (2010) reviews advances in the production of spider silk proteins.

US 2009/0263430 discloses chemical coupling of the enzyme β-galactosidase to films of a miniature spider silk protein. However, chemical coupling may require conditions which are unfavourable for protein stability and/or function. Proteins containing multiple repeats of a segment derived from the repetitive region of spider silk proteins have been designed to include a RGD cell-binding segment (Bini, E *et al.*, Biomacromolecules 7:3139-3145 (2006)) and/or a R5 peptide (Wong Po Foo, C *et al.*, Proc Natl Acad Sci 103 (25): 9428-9433 (2006)) or other protein segments involved in mineralization (Huang, J *et al.*, Biomaterials 28: 2358-2367 (2007); WO 2006/076711). In these prior art documents, films are formed by solubilizing the fusion proteins in the denaturing organic solvent hexafluoroisopropanol (HFIP) and drying.

US 2005/261479 A1 discloses a method of for purification of recombinant silk proteins consisting of a repetitive fragment and an affinity tag, involving magnetic affinity separation of individual silk proteins from complex mixtures without formation of silk protein fibers or other polymer structures.

Known supporting structures and associated techniques have certain drawbacks with regard to e.g. economy, efficiency, stability, regenerating capacity, bioactivity and biocompatibility.

Summary of the invention

It is an object of the present invention to provide novel recombinant fusion proteins which are capable of selective interaction with an organic target.

It is an object of the present invention to provide a novel protein structure that is capable of selective interaction with an organic target.

It is also an object of the present invention to provide a protein structure that is capable of selective interaction with an organic target, wherein the structure is formed without use of harsh solvents which may have an unpredictable effect on the secondary structure or activity of the protein and/or remain in the protein structure.

It is one object of the present invention to provide a stable protein structure that is capable of selective interaction with an organic target, which protein structure can readily be regenerated after use, e.g. with chemical treatment.

It is another object of the present invention to provide a stable protein structure that is biocompatible and suitable for cell culture and as an implant.

It is yet another object of the invention to provide a protein structure with a high density of evenly spaced functionalities that are capable of selective interaction with an organic target.

It is a further object of the invention to provide a protein structure which maintains its selective binding ability upon storage at +4°C or at room temperature for months.

It is also an object of the invention to provide a protein structure which is autoclavable, i.e. maintains its selective binding ability after sterilizing heat treatment.

It is a further object of the present invention to provide a protein structure that is useful in protein microarray diagnostics.

For these and other objects that will be evident from the following disclosure, the present invention provides according to a first aspect a fusion protein and a protein structure consisting of polymers comprising as a repeating structural unit the fusion protein as set out in the claims.

According to a related aspect, the present invention provides an isolated nucleic acid encoding the fusion protein and a method of producing the fusion protein as set out in the claims.

The present invention provides according to another aspect a method for providing a protein structure as set out in the claims.

The present invention provides according to a further aspect an affinity medium as set out in the claims.

The present invention provides according to one aspect a cell scaffold material as set out in the claims. According to a related aspect, the present invention also provides a combination of cells and a cell scaffold material according to the claims.

The present invention provides according to an aspect novel uses of a protein structure and a fusion protein as set out in the claims.

The present invention provides according to another aspect a method for separation of an organic target from a sample as set out in the claims.

The present invention provides according to a further aspect a method for immobilization and optionally cultivation of cells as set out in the claims.

Brief description of the drawings

Fig. 1 shows a sequence alignment of spidroin C-terminal domains.

Fig. 2 shows a sequence alignment of spidroin N-terminal domains.

Fig. 3 shows binding of Alexa647-labelled antigen to a fusion protein according to the invention.

Fig. 4 shows binding of biotinylated antigen to a fusion protein according to the invention, detected with Alexa647-labelled streptavidin.

Fig. 5 shows microscopic pictures of silk fused antibody fragments in foam format.

Fig. 6 shows an antigen binding analysis of pure and silk fused antibody fragments.

List of appended sequences

SEQ ID NO	
1	4Rep
2	4RepCT
3	NT4Rep
4	NT5Rep
5	NT4RepCTHis
6	NT
7	CT
8	consensus NT sequence
9	consensus CT sequence
10	repetitive sequence from *Euprosthenops australis* MaSp1
11	consensus G segment sequence 1
12	consensus G segment sequence 2
13	consensus G segment sequence 3
14	CT *Euprosthenops sp* MaSp1
15	CT *Euprosthenops australis* MaSp1
16	CT *Argiope trifasciata* MaSp1
17	CT *Cyrtophora moluccensis* Sp1
18	CT *Latrodectus geometricus* MaSp1
19	CT *Latrodectus hesperus* MaSp1

SEQ ID NO	
20	CT *Macrothele holsti* Sp1
21	CT *Nephila clavipes* MaSp1
22	CT *Nephila pilipes* MaSp1
23	CT *Nephila madagascariensis* MaSp1
24	CT *Nephila senegalensis* MaSp1
25	CT *Octonoba varians* Sp1
26	CT *Psechrus sinensis* Sp1
27	CT *Tetragnatha kauaiensis* MaSp1
28	CT *Tetragnatha versicolor* MaSp1
29	CT *Araneus bicentenarius* Sp2
30	CT *Argiope amoena* MaSp2
31	CT *Argiope aurantia* MaSp2
32	CT *Argiope trifasciata* MaSp2
33	CT *Gasteracantha mammosa* MaSp2
34	CT *Latrodectus geometricus* MaSp2
35	CT *Latrodectus hesperus* MaSp2
36	CT *Nephila clavipes* MaSp2
37	CT *Nephila madagascariensis* MaSp2
38	CT *Nephila senegalensis* MaSp2
39	CT *Dolomedes tenebrosus* Fb1
40	CT *Dolomedes tenebrosus* Fb2
41	CT *Araneus diadematus* ADF-1
42	CT *Araneus diadematus* ADF-2
43	CT *Araneus diadematus* ADF-3
44	CT *Araneus diadematus* ADF-4
45	NT *Euprosthenops australis* MaSp1
46	NT *Latrodectus geometricus* MaSp1
47	NT *Latrodectus hesperus* MaSp1
48	NT *Nephila clavipes* MaSp1
49	NT *Argiope trifasciata* MaSp2
50	NT *Latrodectus geometricus* MaSp2
51	NT *Latrodectus hesperus* MaSp2

SEQ ID NO

52	NT *Nephila inaurata madagascariensis* MaSp2
53	NT *Nephila clavipes* MaSp2
54	NT *Argiope bruennichi* cylindriform spidroin 1
55	NT *Nephila clavata* cylindriform spidroin 1
56	NT *Latrodectus hesperus* tubuliform spidroin
57	NT *Nephila clavipes* flagelliform silk protein
58	NT *Nephila inaurata madagascariensis* flagelliform silk protein
59	$His_6ScFvRep_4CT$ (DNA)
60	$His_6Rep_4CTScFv$ (DNA)
61	$His_6ScFvRep_4CT$
62	$His_6Rep_4CTScFv$
63	$His_6ScFvCT$
64	$His_6CTScFv$
65	$His_6ScFvNT\text{-}CT$
66	$His_6NT\text{-}CTScFv$
67	$His_6ScFvNTRep_4CT$
68	$His_6NTRep_4CTScFv$
69	$His_6ScFvNTNT\text{-}CT$
70	$His_6NTNT\text{-}CTScFv$
71	His6-scFv1-NTCT (DNA)
72	His6-scFv1-NTCT
73	His6-scFv1-CT (DNA)
74	His6-scFv1-CT

Detailed description of the invention

The present invention is generally based on the insight that solid protein structures capable of selective interaction with an organic target can be prepared in the form of polymers of a recombinant fusion protein as a repeating structural unit. The fusion protein is comprising at least one immunoglobulin (Ig) fragment that is capable of selective interaction with the organic target (an antigen/epitope), and a moiety corresponding to at least the C-terminal fragment of a spider silk protein. Surprisingly, the moiety derived

from the spider silk protein can be induced to rearrange structurally and as a result form polymeric, solid structures, while the moiety comprising the immunoglobulin fragment(s), comprising e.g. a paratope, is not structurally rearranged but maintains its desirable structure and function, i.e. capability of selective interaction with the organic target. The protein structures can be obtained without a chemical coupling step or a denaturing method step, which facilitates the procedure and improves the chances of obtaining a fusion protein with maintained functionality of its moieties, in particular when the functions are dependent on the secondary structure of the moieties. The formation of these fusion protein polymers can be tightly controlled, and this insight has been developed into further novel protein structures, methods of producing the protein structures and uses of the protein structures in various applications and methods.

The fusion protein according to the invention thus harbors both the desired selective interaction activity and an internal solid support activity that is employed in the protein structure under physiological conditions. It must be considered as surprising that the binding activity of the fusion protein is maintained although the moiety comprising the immunoglobulin fragment(s) is covalently attached to the spidroin moiety when the latter is structurally rearranged to form polymeric, solid structures. In fact, the heat and/or chemical stability and/or binding activity of the moiety providing the selective interaction activity may be increased when integrated in a fusion protein structure according to the invention. The protein structure also provides a high and predictable density of the selective interaction activity towards an organic target. Losses of valuable protein moieties with selective interaction activity are minimized, since all expressed protein moieties are associated with the solid support.

The polymers which are formed from the fusion proteins according to the invention are solid structures and are useful for their physical properties, especially the useful combination of high strength, elasticity and light weight. A particularly useful feature is that the spidroin-derived moieties of the fusion protein are biochemically robust and suitable for regeneration, e.g. with acid, base or chaotropic agents, and suitable for heat sterilization, e.g. autoclaving

at 120°C for 20 min. The polymers are also useful for their ability to support cell adherence and growth. The properties derived from dragline silk are attractive in development of new materials for medical or technical purposes. In particular, protein structures according to the invention are useful in preparative and analytical separation procedures, such as chromatography, cell capture, selection and culture, active filters, and diagnostics.

By way of a preferred example, protein structures according to the invention are also useful for immobilizing antibody fragments in protein microarray diagnostics. Among many advantages which are understood from the present disclosure, it is contemplated that the protein structures according to the invention provide an increased sensitivity. Many diseases are today difficult to diagnose and select correct treatment for. In the arena of multiplexed molecular diagnostics, one can demonstrate a trend over time from DNA to mRNA and now to proteins. Because the information content of proteins is far richer than that of nucleic acids, the potential for more refined diagnoses based on protein patterns is the key to solve the more difficult-to-diagnose disease states as well as the personalized medicine needs. In addition, these diagnoses should be more able to reflect temporal changes in disease and health of a patient's status, unattainable by the static view afforded by germinal DNA.

By thorough investigation of changes in protein content of patient samples (e.g. serum) the understanding of disease-associated changes on a molecular level will help elucidating the underlying mechanisms of disease biology. A survey of the disease related molecular profile could serve as a foundation for improved diagnosis, prognosis and classification of patients. Also, it could be a helpful tool for selecting patients eligible for a particular therapy and monitoring the effects of therapeutic interventions. Specific protein domains, such as engineered antibody fragments, e.g. Single chain Fragment Variable (ScFv), are invaluable tools for analysis of the specific protein content within a sample. One of the most challenging tasks is immobilizing the antibody fragments onto surfaces in such a way that their three-dimensional structure, functionality and binding sites are maintained and accessible. Many important disease markers are proteins that are low

abundant in easily obtained samples such as serum. In order to achieve highly accurate molecular profiling, one therefore has to increase the sensitivity of current conventional technologies. Herein we describe a new strategy for immobilisation of antibody fragments onto a protein-based environment made of recombinant spider silk. This mild immobilisation technique help to keep the antibody fragment stable and hinder denaturation, and thereby increases the sensitivity to specific proteins in a patient sample.

Spider silk has very attractive physical and physiological properties. The recombinant miniature spider silk protein Rep_4CT can be produced in *Escherichia coli* and purified under non-denaturing conditions. The pure Rep_4CT can be further processed into various solid structures, or formats, such as fibers, transparent films and three-dimensional porous foams. Other protein domains can be produced in fusion with CT or Rep_4CT, and thereafter processed into solid formats that are functionalized with specific protein functions. In this way, antibody fragments can be covalently linked to CT or Rep_4CT, and thereafter processed into small, yet strong, spots that are functionalised with antigen binding functions. These silk-immobilised antibody fragments can also be spotted onto a microarray chip surface, and used to detect disease molecules in a body sample, e.g. serum.

Using this strategy the antibody fragments are contained in a protein-based environment and the major fraction of antibody fragments will be in its active form. The new strategy can be compared to the conventional direct drying of antibody fragments onto a surface, where a larger fraction of fragments will be randomly orientated and denatured and, hence, not able to bind antigen. Moreover, when linked to the spider silk, the antibody fragment will be oriented with the antigen binding site towards the molecules in the solution. Since the sensitivity is coupled to the number of active antibody fragments, the higher the fraction of available and active antibody fragments, the higher the sensitivity.

Protein structures according to the invention are also useful in medical devices, such as implants and medical products, such as wound closure systems, band-aids, sutures, wound dressings, and scaffolds for cell immobilization, cell culture, tissue engineering and guided cell regeneration.

The present invention provides a recombinant fusion protein that is capable of selective interaction with an organic target, which fusion protein is comprising the moieties **B** and **CT**, and optionally **REP** and/or **NT**. The present invention also provides a protein structure that is capable of selective interaction with an organic target, wherein said protein structure is a polymer comprising, and optionally consisting of, the recombinant fusion protein according to the invention, i.e. comprising, and optionally consisting of, the moieties **B** and **CT**, and optionally **REP** and/or **NT**.

Although the **CT**, **REP** and **NT** moieties of the fusion proteins in the examples by necessity relate to specific proteins, e.g. proteins derived from major spidroin 1 (MaSp1) from *Euprosthenops australis*, it is considered that the present disclosure is applicable to any structurally similar moieties for the purpose of producing fusion protein structures according to the invention. Furthermore, although the **B** moiety which provides the selective interaction activity of the fusion proteins in the examples by necessity relate to specific protein moieties, e.g. moieties derived from immunoglobulins, it is considered that the present disclosure is applicable to any structurally and/or functionally similar **B** moiety for the purpose of producing fusion protein structures according to the invention, capable of selective interaction with an organic target.

Specific fusion proteins according to the invention are defined by the formulas $\mathbf{B_x}$-CT-$\mathbf{B_z}$, $\mathbf{B_x}$-REP-$\mathbf{B_y}$-CT-$\mathbf{B_z}$ and $\mathbf{B_x}$-CT-$\mathbf{B_y}$-REP-$\mathbf{B_z}$, wherein x, y and z are integers from 0 to 5; and $x+y+z \geq 1$, optionally further containing one **NT** moiety at either end of the fusion protein or between any two protein moieties in the fusion protein. If $x+y+z > 1$, i.e. if there are two or more **B** moieties, they may be identical or different. The two or more **B** moieties may have capacity of selective interaction with the same organic target or with different organic targets. It is preferred that the two or more **B** moieties are substantially identical, each having capacity of selective interaction with the same organic target. Alternatively, it is preferred that the two or more **B** moieties are not identical, and that they together provide the capacity of selective interaction with the organic target.

In preferred fusion proteins according to the invention, x, y and z are integers from 0 to 2, preferably from 0 to 1. In certain preferred fusion proteins according to the invention, y = 0. In more preferred specific fusion proteins according to the invention, y = 0 and either x or z are 0, i.e. the fusion proteins are defined by the formulas **B_x-CT**, **CT-B_z**, **B_x-REP-CT**, **B_x-CT-REP**, **REP-CT-B_z** and **CT-REP-B_z**, wherein x and z are integers from 1 to 5. In preferred fusion proteins according to the invention, y = 0, x and z are integers from 0 to 1; and x+z = 1. Thus, certain preferred fusion proteins according to the invention are defined by the formulas **B-CT**, **CT-B**, **B-REP-CT**, **B-CT-REP**, **REP-CT-B** and **CT-REP-B**. In preferred fusion proteins according to the invention, the optional **REP** moiety is missing. In fusion proteins lacking a REP moiety, non-specific binding of the B moiety to other molecules than its antigen target has advantageously been observed to decrease. It is particularly surprising that solid structures are formed spontaneously from fusion proteins lacking a REP moiety. In further preferred fusion proteins according to the invention, the optional **NT** moiety is missing.

The term "fusion protein" implies here a protein that is made by expression from a recombinant nucleic acid, i.e. DNA or RNA that is created artificially by combining two or more nucleic acid sequences that would not normally occur together (genetic engineering). The fusion proteins according to the invention are recombinant proteins, and they are therefore not identical to naturally occurring proteins. In particular, wildtype spidroins are not fusion proteins according to the invention, because they are not expressed from a recombinant nucleic acid as set out above. The combined nucleic acid sequences encode different proteins, partial proteins or polypeptides with certain functional properties. The resulting fusion protein, or recombinant fusion protein, is a single protein with functional properties derived from each of the original proteins, partial proteins or polypeptides. Furthermore, the fusion protein according to the invention and the corresponding genes are chimeric, i.e. the protein/gene moieties are derived from at least two different species. The **CT** moiety, as well as the optional **REP** and **NT** moiety, are all derived from a spider silk protein. For avoidance of doubt, the **B** moiety according to the invention is a non-spidroin protein or polypeptide, i.e. it is not

derived from a spider silk protein. In particular, the **B** moiety according to the invention is not derived from the C-terminal, repetitive or N-terminal fragments of a spider silk protein.

The fusion protein typically consists of from 170 to 2000 amino acid residues, such as from 170 to 1000 amino acid residues, such as from 170 to 600 amino acid residues, preferably from 170 to 500 amino acid residues, such as from 170 to 400 amino acid residues. The small size is advantageous because longer proteins containing spider silk protein fragments may form amorphous aggregates, which require use of harsh solvents for solubilisation and polymerisation. The recombinant fusion protein may contain more than 2000 residues, in particular in cases where the spider silk protein more than one **B** moiety and/or when it contains a **NT** moiety, e.g. 1-2 **NT** moieties.

The terms "spidroins" and "spider silk proteins" are used interchangeably throughout the description and encompass all known spider silk proteins, including major ampullate spider silk proteins which typically are abbreviated "MaSp", or "ADF" in the case of *Araneus diadematus*. These major ampullate spider silk proteins are generally of two types, 1 and 2. These terms furthermore include non-natural proteins with a high degree of identity and/or similarity to the known spider silk proteins.

Consequently, the term "non-spidroin" implies proteins that are not derived from a spider silk protein, i.e. with a low (or no) degree of identity and/or similarity to spider silk proteins.

The protein structure according to the invention is capable of selective interaction with an organic target. This capacity resides in the fusion protein according to the invention, and more specifically in the **B** moiety of the fusion protein. Any interactions of the **CT** moiety, as well as the optional **REP** and **NT** moiety, with organic molecules are not encompassed by the term "capable of selective interaction with an organic target". For avoidance of doubt, the term "capable of selective interaction with an organic target" does not encompass dimerization, oligomerization or polymerization of the fusion proteins according to the invention that rely on interactions involving the **CT** moiety, as well as the optional **REP** and **NT** moieties.

The term "organic target" encompasses all chemical molecules containing carbon with the exception of what is traditionally considered inorganic molecules by the skilled person, e.g. carbonates, simple oxides of carbon, cyanides, diamond and graphite. For avoidance of doubt, inorganic molecules, salts and ions, such as silica and calcium chloride, are not organic. The organic target may be a complex containing or consisting of organic molecules, e.g. a receptor complex on a cell surface. The organic target may be a monomer, dimer, oligomer or polymer of one or more organic molecule types, which may be held together by covalent bonds or other types of association. It may of course also simply be a single organic molecule. Preferred organic targets according to the invention include, but are not limited to, nucleic acids, proteins and polypeptides, lipids and carbohydrates, as well as combinations thereof. Further preferred organic targets according to the invention include, but are not limited to, immunoglobulins, molecules comprising immunoglobulin or derivatives thereof, albumin, molecules comprising albumin or derivatives thereof, biotin, molecules comprising biotin or derivatives or analogues thereof, and biological disease markers, e.g. from blood, serum, urine, saliva or other samples from body tissues.

In the context of the present invention, “specific” or “selective” interaction of a ligand, e.g. a **B** moiety of the fusion protein according to the invention with its target means that the interaction is such that a distinction between specific and non-specific, or between selective and non-selective, interaction becomes meaningful. The interaction between two proteins is sometimes measured by the dissociation constant. The dissociation constant describes the strength of binding (or affinity) between two molecules. Typically the dissociation constant between an antibody and its antigen (epitope) is from 10^{-7} to 10^{-11} M. However, high specificity does not necessarily require high affinity. Molecules with low affinity (in the molar range) for its counterpart have been shown to be as specific as molecules with much higher affinity. In the case of the present invention, a specific or selective interaction refers to the extent to which a particular method can be used to determine the presence and/or amount of a specific protein, the target protein or a fragment thereof, under given conditions in the presence of other

proteins in a sample of a naturally occurring or processed biological or biochemical fluid. In other words, specificity or selectivity is the capacity to distinguish between related proteins. Specific and selective are sometimes used interchangeably in the present description.

The fusion protein according to the invention may also contain one or more linker peptides. The linker peptide(s) may be arranged between any moieties of the fusion protein, e.g. between two **B** moieties, between **B** and **CT** moieties, between **CT** and **REP** moieties, and between **B** and **REP** moieties, or may be arranged at either terminal end of the fusion protein. If the **B** moiety contains two or more Ig fragments, the linker peptide(s) may also be arranged in between two Ig fragments. If the fusion protein contains two or more **B** moieties, the linker peptide(s) may also be arranged in between two **B** moieties. The linker(s) may provide a spacer between the functional units of the fusion protein, but may also constitute a handle for identification and purification of the fusion protein, e.g. a His and/or a Trx tag. If the fusion protein contains two or more linker peptides for identification and purification of the fusion protein, it is preferred that they are separated by a spacer sequence, e.g. His_6-spacer-His_6-. The linker may also constitute a signal peptide, such as a signal recognition particle, which directs the fusion protein to the membrane and/or causes secretion of the fusion protein from the host cell into the surrounding medium. The fusion protein may also include a cleavage site in its amino acid sequence, which allows for cleavage and removal of the linker(s) and/or other relevant moieties, typically the **B** moiety or moieties. Various cleavage sites are known to the person skilled in the art, e.g. cleavage sites for chemical agents, such as CNBr after Met residues and hydroxylamine between Asn-Gly residues, cleavage sites for proteases, such as thrombin or protease 3C, and self-splicing sequences, such as intein self-splicing sequences.

The **CT** and **B** are linked directly or indirectly to one another. A direct linkage implies a direct covalent binding between the moieties without intervening sequences, such as linkers. An indirect linkage also implies that the moieties are linked by covalent bonds, but that there are intervening

sequences, such as linkers and/or one or more further moieties, e.g. a **REP** and/or a **NT** moiety.

The **B** moiety or moieties may be arranged internally or at either end of the fusion protein, i.e. C-terminally arranged or N-terminally arranged. It is preferred that the **B** moiety or moieties are arranged at the N-terminal end of the fusion protein. If the fusion protein contains one or more linker peptide(s) for identification and purification of the fusion protein, e.g. a His or Trx tag(s), it is preferred that it is arranged at the N-terminal end of the fusion protein.

A preferred fusion protein has the form of an N-terminally arranged **B** moiety, coupled by a linker peptide of 1-30 amino acid residues, such as 1-10 amino acid residues, to C-terminally arranged **REP** and **CT** moieties. The linker peptide may contain a cleavage site. Optionally, the fusion protein has an N-terminal or C-terminal linker peptide, which may contain a purification tag, such as a His tag, and a cleavage site.

Another preferred fusion protein has the form of an N-terminally arranged **B** moiety coupled directly to C-terminally arranged **REP** and **CT** moieties. Optionally, the fusion protein has an N-terminal or C-terminal linker peptide, which may contain a purification tag, such as a His tag, and a cleavage site.

The protein structure according to the invention is a polymer comprising as a repeating structural unit recombinant fusion proteins according to the invention, which implies that it contains an ordered plurality of fusion proteins according to the invention, typically well above 100 fusion protein units, e.g. 1000 fusion protein units or more. Optionally, the polymer may comprise as a further repeating structural unit complementary proteins without a **B** moiety, preferably proteins derived from spider silk. This may be advantageous if the **B** moiety of the fusion protein is large and/or bulky. These complementary proteins typically comprise a **REP** moiety and a **CT** moiety, and optionally an **NT** moiety, e.g. 1-2 **NT** moieties. Preferred complementary proteins according to the invention can have any of the structures set out herein with a deleted **B** moiety. It is preferred that the complementary fusion protein is substantially identical to the fusion protein with a deleted **B** moiety. However, it is preferred that the protein structure

according to the invention is a polymer consisting of recombinant fusion proteins according to the invention as a repeating structural unit, i.e. that the protein structure according to the invention is a polymer of the recombinant fusion protein according to the invention.

The magnitude of fusion units in the polymer implies that the protein structure obtains a significant size. In a preferred embodiment, the protein structure has a size of at least 0.1 µm in at least two dimensions. Thus, the term "protein structure" as used herein relates to fusion protein polymers having a thickness of at least 0.1 µm, preferably macroscopic polymers that are visible to the human eye, i.e. having a thickness of at least 1 µm. The term "protein structure" does not encompass unstructured aggregates or precipitates. While monomers of the fusion protein are water soluble, it is understood that the protein structures according to the invention are solid structures, i.e. not soluble in water. The protein structures are polymers comprising as a repeating structural unit monomers of the recombinant fusion proteins according to the invention.

It is preferable that the protein structure according to the invention is in a physical form selected from the group consisting of fiber, film, foam, net, mesh, sphere and capsule.

It is preferable that the protein structure according to the invention is a fiber or film with a thickness of at least 1 nm, such as at least 0.1 µm, preferably at least 1 µm. It is preferred that the fiber or film has a thickness in the range of 1 nm - 400 µm, such as 1-400 µm, and preferably 60-120 µm. It is preferred that fibers have a length in the range of 0.5-300 cm, preferably 1-100 cm. Other preferred ranges are 0.5-30 cm and 1-20 cm. The fiber has the capacity to remain intact during physical manipulation, i.e. can be used for spinning, weaving, twisting, crocheting and similar procedures. The film is advantageous in that it is coherent and adheres to solid structures, e.g. the plastics in microtiter plates. This property of the film facilitates washing and regeneration procedures and is very useful for separation purposes.

It is also preferred that the protein structure according to the invention has a tensile strength above 1 MPa, preferably above 2 MPa, more preferably 10 MPa or higher. It is preferred that the protein structure according to the

invention has a tensile strength above 100 MPa, more preferably 200 MPa or higher.

The **CT** moiety is a protein fragment containing from 70 to 120 amino acid residues and is derived from the C-terminal fragment of a spider silk protein. The expression "derived from" implies in the context of the **CT** moiety according to the invention that it has a high degree of similarity to the C-terminal amino acid sequence of spider silk proteins. As shown in Fig 1, this amino acid sequence is well conserved among various species and spider silk proteins, including MaSp1 and MaSp2. A consensus sequence of the C-terminal regions of MaSp1 and MaSp2 is provided as SEQ ID NO: 9. In Fig 1, the following MaSp proteins are aligned, denoted with GenBank accession entries where applicable (SEQ ID NOS: 14-44):

TABLE 1 - Spidroin **CT** moieties

Species and spidroin protein	Entry
Euprosthenops sp MaSp1 (Pouchkina-Stantcheva, NN & McQueen-Mason, SJ, *ibid*)	Cthyb_Esp
Euprosthenops australis MaSp1	CTnat_Eau
Argiope trifasciata MaSp1	AF350266_At1
Cyrtophora moluccensis Sp1	AY666062_Cm1
Latrodectus geometricus MaSp1	AF350273_Lg1
Latrodectus hesperus MaSp1	AY953074_Lh1
Macrothele holsti Sp1	AY666068_Mh1
Nephila clavipes MaSp1	U20329_Nc1
Nephila pilipes MaSp1	AY666076_Np1
Nephila madagascariensis MaSp1	AF350277_Nm1
Nephila senegalensis MaSp1	AF350279_Ns1
Octonoba varians Sp1	AY666057_Ov1
Psechrus sinensis Sp1	AY666064_Ps1
Tetragnatha kauaiensis MaSp1	AF350285_Tk1
Tetragnatha versicolor MaSp1	AF350286_Tv1

Species and spidroin protein	Entry
Araneus bicentenarius Sp2	ABU20328_Ab2
Argiope amoena MaSp2	AY365016_Aam2
Argiope aurantia MaSp2	AF350263_Aau2
Argiope trifasciata MaSp2	AF350267_At2
Gasteracantha mammosa MaSp2	AF350272_Gm2
Latrodectus geometricus MaSp2	AF350275_Lg2
Latrodectus hesperus MaSp2	AY953075_Lh2
Nephila clavipes MaSp2	AY654293_Nc2
Nephila madagascariensis MaSp2	AF350278_Nm2
Nephila senegalensis MaSp2	AF350280_Ns2
Dolomedes tenebrosus Fb1	AF350269_DtFb1
Dolomedes tenebrosus Fb2	AF350270_DtFb2
Araneus diadematus ADF-1	U47853_ADF1
Araneus diadematus ADF-2	U47854_ADF2
Araneus diadematus ADF-3	U47855_ADF3
Araneus diadematus ADF-4	U47856_ADF4

It is not critical which specific **CT** moiety is present in spider silk proteins according to the invention, as long as the **CT** moiety is not entirely missing. Thus, the **CT** moiety according to the invention can be selected from any of the amino acid sequences shown in Fig 1 and Table 1 (SEQ ID NOS: 14-44) or sequences with a high degree of similarity. A wide variety of C-terminal sequences can be used in the spider silk protein according to the invention.

The sequence of the **CT** moiety according to the invention has at least 50% identity, preferably at least 60%, more preferably at least 65% identity, or even at least 70% identity, to the consensus amino acid sequence SEQ ID NO: 9, which is based on the amino acid sequences of Fig 1 (SEQ ID NOS: 14-44).

The term "% identity", as used throughout the specification and the appended claims, is calculated as follows. The query sequence is aligned to the target sequence using the CLUSTAL W algorithm (Thompson, J.D., Higgins, D.G. and Gibson, T.J., Nucleic Acids Research, 22: 4673-4680 (1994)). A comparison is made over the window corresponding to the shortest of the aligned sequences. The amino acid residues at each position are compared, and the percentage of positions in the query sequence that have identical correspondences in the target sequence is reported as % identity.

The term "% similarity", as used throughout the specification and the appended claims, is calculated as described for "% identity", with the exception that the hydrophobic residues Ala, Val, Phe, Pro, Leu, Ile, Trp, Met and Cys are similar; the basic residues Lys, Arg and His are similar; the acidic residues Glu and Asp are similar; and the hydrophilic, uncharged residues Gln, Asn, Ser, Thr and Tyr are similar. The remaining natural amino acid Gly is not similar to any other amino acid in this context.

Throughout this description, alternative embodiments according to the invention fulfill, instead of the specified percentage of identity, the corresponding percentage of similarity. Other alternative embodiments fulfill the specified percentage of identity as well as another, higher percentage of similarity, selected from the group of preferred percentages of identity for each sequence. For example, a sequence may be 70% similar to another sequence; or it may be 70% identical to another sequence; or it may be 70% identical and 90% similar to another sequence.

A representative **CT** moiety according to the invention is the *Euprosthenops australis* sequence SEQ ID NO: 7, Thus, according to a preferred aspect of the invention, the **CT** moiety has at least 80%, preferably at least 90%, such as at least 95%, identity to SEQ ID NO: 7 or any individual amino acid sequence of Fig 1 and Table 1 (SEQ ID NOS: 14-44). In preferred aspects of the invention, the **CT** moiety is identical to SEQ ID NO: 7 or any individual amino acid sequence of Fig 1 and Table 1.

The **CT** moiety typically consists of from 70 to 120 amino acid residues. It is preferred that the **CT** moiety contains at least 70, or more than 80, preferably more than 90, amino acid residues. It is also preferred that the

CT moiety contains at most 120, or less than 110 amino acid residues. A typical **CT** moiety contains approximately 100 amino acid residues.

The optional **REP** moiety is a protein fragment containing from 70 to 300 amino acid residues and is derived from the repetitive fragment of a spider silk protein. This implies that the **REP** moiety has a repetitive character, alternating between alanine-rich stretches and glycine-rich stretches. The **REP** moiety generally contains more than 70, such as more than 140, and less than 300, preferably less than 240, such as less than 200, amino acid residues, and can itself be divided into several **L** (linker) segments, **A** (alanine-rich) segments and **G** (glycine-rich) segments, as will be explained in more detail below. Typically, said linker segments, which are optional, are located at the **REP** moiety terminals, while the remaining segments are in turn alanine-rich and glycine-rich. Thus, the **REP** moiety can generally have either of the following structures, wherein n is an integer:

$\mathbf{L(AG)_nL}$, such as $\mathbf{LA_1G_1A_2G_2A_3G_3A_4G_4A_5G_5L}$;

$\mathbf{L(AG)_nAL}$, such as $\mathbf{LA_1G_1A_2G_2A_3G_3A_4G_4A_5G_5A_6L}$;

$\mathbf{L(GA)_nL}$, such as $\mathbf{LG_1A_1G_2A_2G_3A_3G_4A_4G_5A_5L}$; or

$\mathbf{L(GA)_nGL}$, such as $\mathbf{LG_1A_1G_2A_2G_3A_3G_4A_4G_5A_5G_6L}$.

It follows that it is not critical whether an alanine-rich or a glycine-rich segment is adjacent to the N-terminal or C-terminal linker segments. It is preferred that n is an integer from 2 to 10, preferably from 2 to 8, preferably from 4 to 8, more preferred from 4 to 6, i.e. n=4, n=5 or n=6.

In preferred embodiments, the alanine content of the **REP** moiety according to the invention is above 20%, preferably above 25%, more preferably above 30%, and below 50%, preferably below 40%, more preferably below 35%. This is advantageous, since it is contemplated that a higher alanine content provides a stiffer and/or stronger and/or less extendible structure.

In certain embodiments, the **REP** moiety is void of proline residues, i.e. there are no proline residues in the **REP** moiety.

Now turning to the segments that constitute the **REP** moiety according to the invention, it shall be emphasized that each segment is individual, i.e.

any two **A** segments, any two **G** segments or any two **L** segments of a specific **REP** moiety may be identical or may not be identical. Thus, it is not a general feature of the invention that each type of segment is identical within a specific **REP** moiety. Rather, the following disclosure provides the skilled person with guidelines how to design individual segments and gather them into a **REP** moiety which is thereby considered to be derived from the repetitive fragment of a spider silk protein, and which constitutes a part of a functional fusion protein according to the invention.

Each individual **A** segment is an amino acid sequence having from 8 to 18 amino acid residues. It is preferred that each individual **A** segment contains from 13 to 15 amino acid residues. It is also possible that a majority, or more than two, of the **A** segments contain from 13 to 15 amino acid residues, and that a minority, such as one or two, of the **A** segments contain from 8 to 18 amino acid residues, such as 8-12 or 16-18 amino acid residues. A vast majority of these amino acid residues are alanine residues. More specifically, from 0 to 3 of the amino acid residues are not alanine residues, and the remaining amino acid residues are alanine residues. Thus, all amino acid residues in each individual **A** segment are alanine residues, with no exception or the exception of one, two or three amino acid residues, which can be any amino acid. It is preferred that the alanine-replacing amino acid(s) is (are) natural amino acids, preferably individually selected from the group of serine, glutamic acid, cysteine and glycine, more preferably serine. Of course, it is possible that one or more of the **A** segments are all-alanine segments, while the remaining **A** segments contain 1-3 non-alanine residues, such as serine, glutamic acid, cysteine or glycine.

In a preferred embodiment, each **A** segment contains 13-15 amino acid residues, including 10-15 alanine residues and 0-3 non-alanine residues as described above. In a more preferred embodiment, each **A** segment contains 13-15 amino acid residues, including 12-15 alanine residues and 0-1 non-alanine residues as described above.

It is preferred that each individual **A** segment has at least 80%, preferably at least 90%, more preferably 95%, most preferably 100% identity to an amino acid sequence selected from the group of amino acid residues 7-

19, 43-56, 71-83, 107-120, 135-147, 171-183, 198-211, 235-248, 266-279, 294-306, 330-342, 357-370, 394-406, 421-434, 458-470, 489-502, 517-529, 553-566, 581-594, 618-630, 648-661, 676-688, 712-725, 740-752, 776-789, 804-816, 840-853, 868-880, 904-917, 932-945, 969-981, 999-1013, 1028-1042 and 1060-1073 of SEQ ID NO: 10. Each sequence of this group corresponds to a segment of the naturally occurring sequence of *Euprosthenops australis* MaSp1 protein, which is deduced from cloning of the corresponding cDNA, see WO 2007/078239. Alternatively, each individual **A** segment has at least 80%, preferably at least 90%, more preferably 95%, most preferably 100% identity to an amino acid sequence selected from the group of amino acid residues 143-152, 174-186, 204-218, 233-247 and 265-278 of SEQ ID NO: 3. Each sequence of this group corresponds to a segment of expressed, non-natural spider silk proteins, which proteins have capacity to form silk structures under appropriate conditions. Thus, in certain embodiments according to the invention, each individual **A** segment is identical to an amino acid sequence selected from the above-mentioned amino acid segments. Without wishing to be bound by any particular theory, it is envisaged that **A** segments according to the invention form helical structures or beta sheets.

Furthermore, it has been concluded from experimental data that each individual **G** segment is an amino acid sequence of from 12 to 30 amino acid residues. It is preferred that each individual **G** segment consists of from 14 to 23 amino acid residues. At least 40% of the amino acid residues of each **G** segment are glycine residues. Typically the glycine content of each individual **G** segment is in the range of 40-60%.

It is preferred that each individual **G** segment has at least 80%, preferably at least 90%, more preferably 95%, most preferably 100% identity to an amino acid sequence selected from the group of amino acid residues 20-42, 57-70, 84-106, 121-134, 148-170, 184-197, 212-234, 249-265, 280-293, 307-329, 343-356, 371-393, 407-420, 435-457, 471-488, 503-516, 530-552, 567-580, 595-617, 631-647, 662-675, 689-711, 726-739, 753-775, 790-803, 817-839, 854-867, 881-903, 918-931, 946-968, 982-998, 1014-1027, 1043-1059 and 1074-1092 of SEQ ID NO: 10. Each sequence of this group

corresponds to a segment of the naturally occurring sequence of *Euprosthenops australis* MaSp1 protein, which is deduced from cloning of the corresponding cDNA, see WO 2007/078239. Alternatively, each individual **G** segment has at least 80%, preferably at least 90%, more preferably 95%, most preferably 100% identity to an amino acid sequence selected from the group of amino acid residues 153-173, 187-203, 219-232, 248-264 and 279-296 of SEQ ID NO: 3. Each sequence of this group corresponds to a segment of expressed, non-natural spider silk proteins, which proteins have capacity to form silk structures under appropriate conditions. Thus, in certain embodiments according to the invention, each individual **G** segment is identical to an amino acid sequence selected from the above-mentioned amino acid segments.

In certain embodiments, the first two amino acid residues of each **G** segment according to the invention are not -Gln-Gln-.

There are the three subtypes of the **G** segment according to the invention. This classification is based upon careful analysis of the *Euprosthenops australis* MaSp1 protein sequence (WO 2007/078239), and the information has been employed and verified in the construction of novel, non-natural spider silk proteins.

The first subtype of the **G** segment according to the invention is represented by the amino acid one letter consensus sequence GQG(G/S)QGG(Q/Y)GG (L/Q)GQGGYGQGA GSS (SEQ ID NO: 11). This first, and generally the longest, **G** segment subtype typically contains 23 amino acid residues, but may contain as little as 17 amino acid residues, and lacks charged residues or contain one charged residue. Thus, it is preferred that this first **G** segment subtype contains 17-23 amino acid residues, but it is contemplated that it may contain as few as 12 or as many as 30 amino acid residues. Without wishing to be bound by any particular theory, it is envisaged that this subtype forms coil structures or 3_1-helix structures. Representative **G** segments of this first subtype are amino acid residues 20-42, 84-106, 148-170, 212-234, 307-329, 371-393, 435-457, 530-552, 595-617, 689-711, 753-775, 817-839, 881-903, 946-968, 1043-1059 and 1074-1092 of SEQ ID NO:

10. In certain embodiments, the first two amino acid residues of each **G** segment of this first subtype according to the invention are not -Gln-Gln-.

The second subtype of the **G** segment according to the invention is represented by the amino acid one letter consensus sequence GQGGQGQG(G/R)Y GQG(A/S)G(S/G)S (SEQ ID NO: 12). This second, generally mid-sized, **G** segment subtype typically contains 17 amino acid residues and lacks charged residues or contain one charged residue. It is preferred that this second **G** segment subtype contains 14-20 amino acid residues, but it is contemplated that it may contain as few as 12 or as many as 30 amino acid residues. Without wishing to be bound by any particular theory, it is envisaged that this subtype forms coil structures. Representative **G** segments of this second subtype are amino acid residues 249-265, 471-488, 631-647 and 982-998 of SEQ ID NO: 10; and amino acid residues 187-203 of SEQ ID NO: 3.

The third subtype of the **G** segment according to the invention is represented by the amino acid one letter consensus sequence G(R/Q)GQG(G/R)YGQG (A/S/V)GGN (SEQ ID NO: 13). This third **G** segment subtype typically contains 14 amino acid residues, and is generally the shortest of the **G** segment subtypes according to the invention. It is preferred that this third **G** segment subtype contains 12-17 amino acid residues, but it is contemplated that it may contain as many as 23 amino acid residues. Without wishing to be bound by any particular theory, it is envisaged that this subtype forms turn structures. Representative **G** segments of this third subtype are amino acid residues 57-70, 121-134, 184-197, 280-293, 343-356, 407-420, 503-516, 567-580, 662-675, 726-739, 790-803, 854-867, 918-931, 1014-1027 of SEQ ID NO: 10; and amino acid residues 219-232 of SEQ ID NO: 3.

Thus, in preferred embodiments, each individual G segment has at least 80%, preferably 90%, more preferably 95%, identity to an amino acid sequence selected from SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13.

In a preferred embodiment of the alternating sequence of **A** and **G** segments of the **REP** moiety, every second **G** segment is of the first subtype, while the remaining **G** segments are of the third subtype, e.g. ...$\mathbf{A}_1\mathbf{G}_{short}\mathbf{A}_2\mathbf{G}_{long}\mathbf{A}_3\mathbf{G}_{short}\mathbf{A}_4\mathbf{G}_{long}\mathbf{A}_5\mathbf{G}_{short}$... In another preferred embodiment of

the **REP** moiety, one **G** segment of the second subtype interrupts the **G** segment regularity *via* an insertion, e.g.

...$\mathbf{A}_1\mathbf{G}_{short}\mathbf{A}_2\mathbf{G}_{long}\mathbf{A}_3\mathbf{G}_{mid}\mathbf{A}_4\mathbf{G}_{short}\mathbf{A}_5\mathbf{G}_{long}$...

Each individual **L** segment represents an optional linker amino acid sequence, which may contain from 0 to 20 amino acid residues, such as from 0 to 10 amino acid residues. While this segment is optional and not functionally critical for the spider silk protein, its presence still allows for fully functional spider silk fusion proteins, forming protein structures according to the invention. There are also linker amino acid sequences present in the repetitive part (SEQ ID NO: 10) of the deduced amino acid sequence of the MaSp1 protein from *Euprosthenops australis*. In particular, the amino acid sequence of a linker segment may resemble any of the described **A** or **G** segments, but usually not sufficiently to meet their criteria as defined herein.

Representative **L** segments are amino acid residues 1-6 and 1093-1110 of SEQ ID NO: 10; and amino acid residues 138-142 of SEQ ID NO: 3, but the skilled person in the art will readily recognize that there are many suitable alternative amino acid sequences for these segments. In one embodiment of the **REP** moiety according to the invention, one of the **L** segments contains 0 amino acids, i.e. one of the **L** segments is void. In another embodiment of the **REP** moiety according to the invention, both **L** segments contain 0 amino acids, i.e. both **L** segments are void. Thus, these embodiments of the **REP** moieties according to the invention may be schematically represented as follows: $(\mathbf{AG})_n\mathbf{L}$, $(\mathbf{AG})_n\mathbf{AL}$, $(\mathbf{GA})_n\mathbf{L}$, $(\mathbf{GA})_n\mathbf{GL}$; $\mathbf{L}(\mathbf{AG})_n$, $\mathbf{L}(\mathbf{AG})_n\mathbf{A}$, $\mathbf{L}(\mathbf{GA})_n$, $\mathbf{L}(\mathbf{GA})_n\mathbf{G}$; and $(\mathbf{AG})_n$, $(\mathbf{AG})_n\mathbf{A}$, $(\mathbf{GA})_n$, $(\mathbf{GA})_n\mathbf{G}$. Any of these **REP** moieties are suitable for use with any **CT** moiety as defined below.

The optional **NT** moiety is a protein fragment containing from 100 to 160 amino acid residues and is derived from the N-terminal fragment of a spider silk protein. The expression "derived from" implies in the context of the **NT** moiety according to the invention that it has a high degree of similarity to the N-terminal amino acid sequence of spider silk proteins. As shown in Fig 2, this amino acid sequence is well conserved among various species and

spider silk proteins, including MaSp1 and MaSp2. In Fig 2, the following spidroin **NT** moieties are aligned, denoted with GenBank accession entries where applicable (SEQ ID NOS: 45-58):

TABLE 2 - Spidroin **NT** moieties

Code	Species and spidroin protein	GenBank acc. no.
Ea MaSp1	*Euprosthenops australis* MaSp 1	AM259067
Lg MaSp1	*Latrodectus geometricus* MaSp 1	ABY67420
Lh MaSp1	*Latrodectus hesperus* MaSp 1	ABY67414
Nc MaSp1	*Nephila clavipes* MaSp 1	ACF19411
At MaSp2	*Argiope trifasciata* MaSp 2	AAZ15371
Lg MaSp2	*Latrodectus geometricus* MaSp 2	ABY67417
Lh MaSp2	*Latrodectus hesperus* MaSp 2	ABR68855
Nim MaSp2	*Nephila inaurata madagascariensis* MaSp 2	AAZ15322
Nc MaSp2	*Nephila clavipes* MaSp 2	ACF19413
Ab CySp1	*Argiope bruennichi* cylindriform spidroin 1	BAE86855
Ncl CySp1	*Nephila clavata* cylindriform spidroin 1	BAE54451
Lh TuSp1	*Latrodectus hesperus* tubuliform spidroin	ABD24296
Nc Flag	*Nephila clavipes* flagelliform silk protein	AF027972
Nim Flag	*Nephila inaurata* madagascariensis flagelliform silk protein	AF218623 (translated)

Only the part corresponding to the N-terminal moiety is shown for each sequence, omitting the signal peptide. Nc flag and Nlm flag are translated and edited according to Rising A. *et al*. Biomacromolecules 7, 3120-3124 (2006)).

It is not critical which specific **NT** moiety is present in spider silk proteins according to the invention. Thus, the **NT** moiety according to the invention can be selected from any of the amino acid sequences shown in Fig 2 and Table 2 (SEQ ID NOS: 45-58) or sequences with a high degree of similarity. A wide variety of N-terminal sequences can be used in the spider silk protein according to the invention. Based on the homologous sequences of Fig 2, the following sequence constitutes a consensus **NT** amino acid

sequence:
QANTPWSSPNLADAFINSF(M/L)SA(A/I)SSSGAFSADQLDDMSTIG(D/N/Q)T
LMSAMD(N/S/K)MGRSG(K/R)STKSKLQALNMAFASSMAEIAAAESGG(G/Q)
SVGVKTNAISDALSSAFYQTTGSVNPQFV(N/S)EIRSLI(G/N)M(F/L)(A/S)QAS
ANEV (SEQ ID NO: 8).

The sequence of the **NT** moiety according to the invention has at least 50% identity, preferably at least 60% identity, to the consensus amino acid sequence SEQ ID NO: 8, which is based on the amino acid sequences of Fig 2. In a preferred embodiment, the sequence of the **NT** moiety according to the invention has at least 65% identity, preferably at least 70% identity, to the consensus amino acid sequence SEQ ID NO: 8. In preferred embodiments, the **NT** moiety according to the invention has furthermore 70%, preferably 80%, similarity to the consensus amino acid sequence SEQ ID NO: 8.

A representative **NT** moiety according to the invention is the *Euprosthenops australis* sequence SEQ ID NO: 6. According to a preferred embodiment of the invention, the **NT** moiety has at least 80% identity to SEQ ID NO: 6 or any individual amino acid sequence in Fig 2 (SEQ ID NOS: 45-58). In preferred embodiments of the invention, the **NT** moiety has at least 90%, such as at least 95% identity, to SEQ ID NO: 6 or any individual amino acid sequence in Fig 2. In preferred embodiments of the invention, the **NT** moiety is identical to SEQ ID NO: 6 or any individual amino acid sequence in Fig 2 (SEQ ID NOS: 45-58), in particular to Ea MaSp1 (SEQ ID NO: 45).

The **NT** moiety contains from 100 to 160 amino acid residues. It is preferred that the **NT** moiety contains at least 100, or more than 110, preferably more than 120, amino acid residues. It is also preferred that the **NT** moiety contains at most 160, or less than 140 amino acid residues. A typical **NT** moiety contains approximately 130-140 amino acid residues.

The **B** moiety is a protein or polypeptide fragment comprising more than 15 amino acid residues, such as 15-22 amino acid residues. The **B** moiety is preferably comprising more than 30 amino acid residues, such as more than 50 amino acid residues, such as more than 100 amino acid residues. The **B** moiety is preferably comprising less than 1000 amino acid

residues, such as less than 400 amino acid residues, more preferably less than 300 amino acid residues. It is capable of selective interaction with the organic target, and it is the **B** moiety in the fusion protein which provides the capacity of selective interaction with the organic target.

The **B** moiety is a non-spidroin moiety. This implies that it is not derived from a spider silk protein, i.e. it has a low (or no) degree of identity and/or similarity to spider silk proteins. The sequence of the **B** moiety according to the invention preferably has less than 30% identity, such as less than 20% identity, preferably less than10% identity, to any of the spidroin amino acid sequences disclosed herein, and specifically to any of SEQ ID NO: 6-10.

It is regarded as within the capabilities of those of ordinary skill in the art to select the **B** moiety. Nevertheless, examples of affinity ligands that may prove useful as **B** moieties, as well as examples of formats and conditions for detection and/or quantification, are given below for the sake of illustration.

The biomolecular diversity needed for selection of affinity ligands may be generated by combinatorial engineering of one of a plurality of possible scaffold molecules, and specific and/or selective affinity ligands are then selected using a suitable selection platform. Non-limiting examples of such structures, useful for generating affinity ligands against the organic target, are immunoglobulins and fragments of immunoglobulins.

The above-mentioned examples include scaffold proteins presenting a single randomized loop used for the generation of novel binding specificities, protein scaffolds with a rigid secondary structure where side chains protruding from the protein surface are randomized for the generation of novel binding specificities, and scaffolds exhibiting a non-contiguous hyper-variable loop region used for the generation of novel binding specificities. For selection of the desired affinity ligand from a pool of variants of any of the scaffold structures mentioned above, a number of selection platforms are available for the isolation of a specific novel ligand against a target protein of choice. Selection platforms include, but are not limited to, phage display (Smith GP (1985) Science 228:1315-1317), ribosome display (Hanes J and Plückthun A (1997) Proc. Natl. Acad. Sci. U.S.A. 94:4937-4942), yeast two-hybrid system

(Fields S and Song O (1989) Nature 340:245-246), yeast display (Gai SA and Wittrup KD (2007) Curr Opin Struct Biol 17:467-473), mRNA display (Roberts RW and Szostak JW (1997) Proc. Natl. Acad. Sci. U.S.A. 94:12297-12302), bacterial display (Daugherty PS (2007) Curr Opin Struct Biol 17:474-480, Kronqvist N *et al.* (2008) Protein Eng Des Sel 1-9, Harvey BR *et al.* (2004) PNAS 101(25):913-9198), microbead display (Nord O *et al.* (2003) J Biotechnol 106:1-13, WO01/05808), SELEX (System Evolution of Ligands by Exponential Enrichment) (Tuerk C and Gold L (1990) Science 249:505-510) and protein fragment complementation assays (PCA) (Remy I and Michnick SW (1999) Proc. Natl. Acad. Sci. U.S.A. 96:5394-5399).

A group of preferred **B** moieties are immunoglobulin fragments and molecules comprising immunoglobulin fragments or derivatives thereof. It is preferred that each immunoglobulin fragment of the **B** moiety is selected from immunoglobulin variable regions. It is further preferred that the **B** moiety is comprising at least one heavy chain variable region (V_H) and at least one light chain variable region (V_L).

A particularly preferred group of **B** moieties are single-chain variable fragments (scFv) of the variable regions of the heavy (V_H) and light (V_L) chains of immunoglobulins, optionally connected with a short linker peptide. The linker peptide is typically containing e.g. 10-25 amino acid residues and is rich in glycine, serine or threonine. The single-chain variable fragments according to the invention lack the constant Fc region found in complete antibody molecules. Preferred single-chain variable fragments according to the invention are thus characterized by that they do not bind to Protein G, but bind to Protein L from *Peptostreptococcus magnus*, since Protein L interacts with the variable region of kappa light chains.

One preferred group of B moieties are the fragment antigen-binding (Fab fragments) from immunoglobulins, i.e. the region on an antibody that binds to antigens. It is composed of one constant and one variable domain of each of the heavy and the light chain. The two variable domains bind the epitope on their specific antigens. A specific variant includes the $F(ab')_2$ fragments, i.e. an immunoglobulin monomer where the Fc fragment has been removed, e.g. by cleavage with pepsin.

Another preferred group of **B** moieties are domain antibodies (dAbs) or single domain antibodies (sdABs), also termed Nanobodies, occurring naturally in heavy chain immunoglobulins from camels. dAbs/sdABs are the smallest known antigen-binding fragments of antibodies, ranging from 11 kDa to 15 kDa. dAbs/sdAbs are the robust variable regions of the heavy (V_H) and/or light (V_L) chains of immunoglobulins. They are highly expressed in microbial cell culture, show favorable biophysical properties including solubility and temperature stability, and are well suited to selection and affinity maturation by *in vitro* selection systems such as phage display. They are also useful to create drugs with prolonged serum half-lives or other pharmacological activities.

Specific fusion proteins and protein structures according to the invention are provided in the Examples. These preferred fusion proteins form the group consisting of SEQ ID NOS 61-70, 72 and 74. Further preferred fusion proteins are having at least 80%, preferably at least 90%, more preferably at least 95%, identity to any of these sequences.

The present invention further provides isolated nucleic acids encoding a fusion protein according to the invention. In particular, specific nucleic acids are provided in the Examples and the appended sequence listing, e.g. SEQ ID NOS 59-60, 71 and 73. Further preferred nucleic acids encode fusion proteins having at least 80%, preferably at least 90%, more preferably at least 95%, identity to any of SEQ ID NOS 61-70, 72 and 74.

The nucleic acids according to the invention are useful for producing the fusion proteins according to the invention. The present invention provides a method of producing a fusion protein. The first step involves expressing in a suitable host a fusion protein according to the invention. Suitable hosts are well known to a person skilled in the art and include e.g. bacteria and eukaryotic cells, such as yeast, insect cell lines and mammalian cell lines. Typically, this step involves expression of a nucleic acid molecule which encodes the fusion protein in *E. coli*.

The second method step involves obtaining a mixture containing the fusion protein. The mixture may for instance be obtained by lysing or

mechanically disrupting the host cells. The mixture may also be obtained by collecting the cell culture medium, if the fusion protein is secreted by the host cell. The thus obtained protein can be isolated using standard procedures. If desired, this mixture can be subjected to centrifugation, and the appropriate fraction (precipitate or supernatant) be collected. The mixture containing the fusion protein can also be subjected to gel filtration, chromatography, e.g. anion exchange chromatography, dialysis, phase separation or filtration to cause separation. Optionally, lipopolysaccharides and other pyrogens are actively removed at this stage. If desired, linker peptides may be removed by cleavage in this step.

Proteins structures, or formats, according to the invention are assembled spontaneously from the fusion proteins according to the invention under suitable conditions, and the assembly into polymers is promoted by the presence of shearing forces and/or an interface between two different phases e.g. between a solid and a liquid phase, between air and a liquid phase or at a hydrophobic/hydrophilic interface, e.g. a mineral oil-water interface. The presence of the resulting interface stimulates polymerization at the interface or in the region surrounding the interface, which region extends into the liquid medium, such that said polymerizing initiates at said interface or in said interface region. Various protein structures can be produced by adapting the conditions during the assembly. For instance, if the assembly is allowed to occur in a container that is gently wagged from side to side, a fiber is formed at the air-water interface. If the mixture is allowed to stand still, a film is formed at the air-water interface. If the mixture is evaporated, a film is formed at the bottom of the container. If oil is added on top of the aqueous mixture, a film is formed at the oil-water interface, either if allowed to stand still or if wagged. If the mixture is foamed, e.g. by bubbling of air or whipping, the foam is stable and solidifies if allowed to dry.

The present invention thus provides a method for providing a protein structure displaying a binding activity towards an organic target. In the first method step, there is provided a recombinant fusion protein according to the invention. The fusion protein may e.g. be provided by expressing it in a suitable host from a nucleic acid according to the invention. In the second

method step, the fusion protein is subjected to conditions to achieve formation of a polymer comprising the recombinant fusion protein. Notably, although the spontaneously assembled protein structures can be solubilized in hexafluoroisopropanol, the solubilized fusion proteins are then not able to spontaneously reassemble into e.g. fibers.

The protein structure is useful as part of an affinity medium for immobilization of an organic target, wherein the **B** moiety is capable of selective interaction with the organic target. A sample, e.g. a biological sample, may be applied to a fusion protein or a protein structure according to the invention which is capable of binding to an organic target present in the biological sample, and the fusion protein or protein structure is then useful for separation of the organic target from the sample. A biological sample, such as blood, serum or plasma which has been removed from a subject may be subjected to detection, separation and/or quantification of the organic target.

The present invention thus provides a method for separation of an organic target from a sample. A sample, e.g. a biological sample such as blood, serum or plasma, containing the organic target is provided. The biological sample may be an earlier obtained sample. If using an earlier obtained sample in a method, no steps of the method are practiced on the human or animal body.

An affinity medium according to the invention is provided, comprising a fusion protein or a protein structure according to the invention. In certain embodiments, the affinity medium is consisting of the fusion protein or protein structure according to the invention. The affinity medium is capable of selective interaction with the organic target by means of the **B** moiety in the fusion protein according to the invention. The affinity medium is contacted with the sample under suitable conditions to achieve binding between the affinity medium and the organic target. Non-bound sample is removed under suitable conditions to maintain selective binding between the affinity medium and the organic target. This method results in an organic target immobilized to the affinity medium, and specifically to the fusion protein, according to the invention.

In a preferred method according to the invention, the fusion protein in the affinity medium is present as a protein structure according to the invention when contacting the affinity medium with the sample to achieve binding between the affinity medium and the organic target. The protein structures according to the invention are advantageous in that they adheres to solid supports, e.g. the plastics in microtiter plates. This property of the protein structure facilitates washing and regeneration procedures and is very useful for separation purposes.

It has surprisingly been observed that the alkali stability of the **B** moiety may even be enhanced when being part of a fusion protein according to the invention in a protein structure according to the invention. This property may be very useful for washing and regeneration purposes, e.g. allowing for high concentrations of NaOH, such as 0.1 M, 0.5 M, 1 M or even above 1 M, e.g. 2 M, and/or for high concentrations of urea, e.g. 6-8 M. The chemical stability may also be useful to allow for repeated cycles of use of the **B** moiety for selective interaction with an organic molecule or affinity purification. Furthermore, it has advantageously been shown that the fusion proteins according to the invention are heat stable. This allows for sterilization by heat with maintained solid protein format/structure as well as binding ability.

Another advantage of the fusion proteins according to the invention is that the resulting protein structure has a high density of **B** moieties. It is contemplated that this high density provides a high binding capacity. Altogether, these properties of the fusions proteins are very attractive for various **B** moieties with good production economy. These properties are also useful in other formats than in traditional gel bead affinity columns, e.g. in filter-like formats.

The immobilized organic target is capable of selective interaction with a second organic target. The method is then further comprising the step of contacting said affinity medium and the immobilized organic target with a second organic target, which is capable of selective interaction with the first organic target, under suitable conditions to achieve binding between the first and second organic targets.

The immobilized organic target is detectable and/or quantifiable. The detection and/or quantification of the organic target may be accomplished in any way known to the skilled person for detection and/or quantification of binding reagents in assays based on various biological or non-biological interactions. The organic targets may be labeled themselves with various markers or may in turn be detected by secondary, labeled affinity ligands to allow detection, visualization and/or quantification. This can be accomplished using any one or more of a multitude of labels, which can be conjugated to the organic target or to any secondary affinity ligand, using any one or more of a multitude of techniques known to the skilled person, and not as such involving any undue experimentation. Non-limiting examples of labels that can be conjugated to organic targets and/or secondary affinity ligands include fluorescent dyes or metals (e.g., fluorescein, rhodamine, phycoerythrin, fluorescamine), chromophoric dyes (e.g., rhodopsin), chemiluminescent compounds (e.g., luminal, imidazole) and bioluminescent proteins (e.g., luciferin, luciferase), haptens (e.g., biotin). A variety of other useful fluorophores and chromophores are described in Stryer L (1968) Science 162:526-533 and Brand L and Gohlke JR (1972) Annu. Rev. Biochem. 41:843-868. Organic targets and/or secondary affinity ligands can also be labeled with enzymes (e.g., horseradish peroxidase, alkaline phosphatase, beta-lactamase), radioisotopes (e.g., ^{3}H, ^{14}C, ^{32}P, ^{35}S or ^{125}I) and particles (e.g., gold). In the context of the present disclosure, “particles” refer to particles, such as metal particles, suitable for labeling of molecules. Further, the affinity ligands may also be labeled with fluorescent semiconductor nanocrystals (quantum dots). Quantum dots have superior quantum yield and are more photostable compared to organic fluorophores and are therefore more easily detected (Chan *et al.* (2002) *Curr Opi Biotech*. 13: 40-46). The different types of labels can be conjugated to an organic target or a secondary affinity ligand using various chemistries, e.g., the amine reaction or the thiol reaction. However, other reactive groups than amines and thiols can be used, e.g., aldehydes, carboxylic acids and glutamine.

If the detection and/or quantification involves exposure to a second organic target or secondary affinity ligand, the affinity medium is washed once

again with buffers to remove unbound secondary affinity ligands. As an example, the secondary affinity ligand may be an antibody or a fragment or a derivative thereof. Thereafter, organic targets may be detected and/or quantified with conventional methods. The binding properties for a secondary affinity ligand may vary, but those skilled in the art should be able to determine operative and optimal assay conditions for each determination by routine experimentation.

The detection, localization and/or quantification of a labeled molecule may involve visualizing techniques, such as light microscopy or immunofluoresence microscopy. Other methods may involve the detection via flow cytometry or luminometry. The method of visualization of labels may include, but is not restricted to, fluorometric, luminometric and/or enzymatic techniques. Fluorescence is detected and/or quantified by exposing fluorescent labels to light of a specific wavelength and thereafter detecting and/or quantifying the emitted light in a specific wavelength region. The presence of a luminescently tagged molecule may be detected and/or quantified by luminescence developed during a chemical reaction. Detection of an enzymatic reaction is due to a color shift in the sample arising from chemical reaction. Those of skill in the art are aware that a variety of different protocols can be modified in order for proper detection and/or quantification.

One available method for detection and/or quantification of the organic target is by linking it or the secondary affinity ligand to an enzyme that can then later be detected and/or quantified in an enzyme immunoassay (such as an EIA or ELISA). Such techniques are well established, and their realization does not present any undue difficulties to the skilled person. In such methods, the biological sample is brought into contact with a protein structure according to the invention which binds to the organic target, which is then detected and/or quantified with an enzymatically labeled secondary affinity ligand. Following this, an appropriate substrate is brought to react in appropriate buffers with the enzymatic label to produce a chemical moiety, which for example is detected and/or quantified using a spectrophotometer, fluorometer, luminometer or by visual means.

The organic target or the secondary affinity ligands can be labeled with radioisotopes to enable detection and/or quantification. Non-limiting examples of appropriate radiolabels in the present disclosure are ^{3}H, ^{14}C, ^{32}P, ^{35}S or ^{125}I. The specific activity of the labeled affinity ligand is dependent upon the half-life of the radiolabel, isotopic purity, and how the label has been incorporated into the affinity ligand. Affinity ligands are preferably labeled using well-known techniques (Wensel TG and Meares CF (1983) in: *Radioimmunoimaging and Radioimmunotherapy* (Burchiel SW and Rhodes BA eds.) Elsevier, New York, pp 185-196). A thus radiolabeled affinity ligand can be used to visualize the organic target by detection of radioactivity. Radionuclear scanning can be performed with e.g. a gamma camera, magnetic resonance spectroscopy, emission tomography, gamma/beta counters, scintillation counters and radiographies.

Thus, the sample may be applied to the protein structure for detection, separation and/or quantification of the organic target. This procedure enables not only detection of the organic target, but may in addition show the distribution and relative level of expression thereof. Optionally, the organic target may be released from the affinity medium and collected. Thus, the use may comprise affinity purification on an affinity medium onto which the organic target has been immobilized. The protein structure may for example be arranged in a column or in well plates (such as 96 well plates), or on magnetic beads, agarose beads or sepharose beads. Further, the use may comprise use of the protein structures on a soluble matrix, for example using a dextran matrix, or use in a surface plasmon resonance instrument, such as a Biacore™ instrument, wherein the analysis may for example comprise monitoring the affinity for the immobilized organic target or a number of potential affinity ligands.

The protein structures according to the invention can be washed and regenerated with various cleaning agents, including acid, base and chaotropic agents. Particularly useful cleaning agents include NaOH, such as 0.1, 0.5 or 1 M NaOH, and urea, such as 6-8 M urea, Since the protein structures according to the invention are surprisingly resistant to chemical treatment and/or sterilizing heat treatment, the methods according to the invention

involving use of the protein structures may comprise a final step of regenerating the protein structure. The methods preferably comprise a final step of regenerating the affinity medium by chemical treatment and/or sterilizing heat treatment. It is preferred that the chemical treatment comprises treatment with NaOH, such as 0.1, 0.5 or 1 M NaOH, and/or urea, such as 6-8 M urea,

Fusion proteins according to the invention can be also be allowed to bind to an organic target in solution, i.e. prior to allowing the fusion protein to polymerize and form a protein structure, such as a film, a foam or a fibre. Both the spidroin-derived moieties (e.g. **CT**) as such and the corresponding fusion proteins incorporating a **B** moiety polymerise into solid structures even in the presence of contaminating proteins, without appreciable incorporation of contaminants into the material, and the functional (**B**) moieties retain their expected binding properties. It is therefore contemplated that the binding properties of the **B** moiety can be used to capture compounds or cells from the surrounding solution and incorporate the captured compounds or cells into or on a protein structure according to the invention.

Thus, in another preferred method according to the invention, the fusion protein in the affinity medium is present in solution when contacting the affinity medium with the sample to achieve binding between the affinity medium and the organic target. The complex of fusion protein bound to the organic target is then allowed to form a fusion protein structure according to the invention.

This method may be particularly useful when the purpose is to “fish out” specific molecules or cells from a solution, e.g. to obtain target molecules from the media in large scale eukaryotic cell production systems when the target proteins are secreted. Since the binding of target molecules and formation of solid structures by the spidroin-derived moieties can take place at physiological conditions and since the spidroin-derived moieties are cytocompatible, the method can be applied repeatedly to an ongoing production process.

The protein structure according to the invention is also useful in separation, immobilization and/or cultivation of cells. A particularly useful

protein structure in this respect is a film, a fiber or a foam. The film is advantageous in that it adheres to solid structures, e.g. the plastics in microtiter plates. This property of the film facilitates washing and regeneration procedures and is very useful for selective detection and separation purposes.

The present invention thus provides a cell scaffold material for cultivation of cells having an organic target that is present on the cell surface. The cell scaffold material is comprising a protein structure according to the invention. In certain embodiments, the cell scaffold material is consisting of the protein structure according to the invention.

It has been found by the present inventors that a cell scaffold material comprising a polymer comprising, and optionally consisting of, the fusion protein according to the invention provides a beneficial environment for the cultivation of cells, and preferably eukaryotic cells, in a variety of different settings. Furthermore, this environment enables the establishment of cultures of cells that are otherwise very difficult, very costly or even impossible to culture in a laboratory, and for the establishment of cell-containing materials useful for tissue engineering and/or transplantation.

The invention also provides a combination of cells, preferably eukaryotic cells, and the cell scaffold material according to the invention. Such a combination according to the invention may be presented in a variety of different formats, and tailored to suit the needs of a specific situation. It is contemplated, for example, that the inventive combination may be useful as a cell-containing implant for the replacement of cells in damaged or diseased tissue.

The cell scaffold material can be utilized to capture cells either directly or indirectly. In direct capture, the **B** moiety is capable of selective interaction with an organic target that is present on the cell surface. Alternatively, the **B** moiety is capable of selective interaction with and is bound to an intermediate organic target, and that intermediate organic target is capable of selective interaction with an organic target that is present on the cell surface. Thus, in indirect capture, the cell scaffold material is further comprising an intermediate organic target, and the **B** moiety is capable of selective

interaction with and is bound to said intermediate organic target. The intermediate organic target, in turn, is capable of selective interaction with the organic target that is present on the cell surface.

In one embodiment of the cell scaffold materials as disclosed herein, the fusion protein is further comprises an oligopeptide cell-binding motif. In connection with the cultivation of certain cells in certain situations, the presence of oligopeptide cell-binding motifs has been observed to improve or maintain cell viability, and the inclusion of such a motif into the cell scaffold material as a part of the spider silk protein is thought to provide additional benefits. The cell-binding motif is an oligopeptide coupled to the rest of the fusion protein via at least one peptide bond. For example, it may be coupled to the N-terminal or the C-terminal of the rest of the fusion protein, or at any position within the amino acid sequence of the rest of the spider silk protein. With regard to the selection of oligopeptidic cell-binding motifs, the skilled person is aware of several alternatives. The coupling of an oligopeptide cell-binding motif to the rest of the spider silk protein is readily accomplished by the skilled person using standard genetic engineering or chemical coupling techniques. Thus, in some embodiments, the cell-binding motif is introduced via genetic engineering, i.e. forming part of a genetic fusion between a nucleic acid encoding a fusion protein and the cell-binding motif. As an additional beneficial characteristic of such embodiments, the cell-binding motif will be present in a 1:1 ratio to the monomers of fusion protein in the polymer making up the cell scaffold material.

The polymer in the cell scaffold material used in the methods or combination described herein may adopt a variety of physical forms, and use of a specific physical form may offer additional advantages in different specific situations. For example, in an embodiment of the methods or combination, said cell scaffold material is in a physical form selected from the group consisting of film, foam, capsules, fiber and fiber-mesh.

The present invention accordingly provides a method for immobilization of cells. A sample e.g. a biological sample such as blood, comprising cells of interest is provided. The biological sample may be an earlier obtained

sample. If using an earlier obtained sample in a method, no steps of the method are practiced on the human or animal body.

The sample is applied to a cell scaffold material according to the invention under suitable conditions to allow selective interaction between the cell scaffold material and an organic target that is present on the surface of the cells of interest. The cells are allowed to immobilize to said cell scaffold material by binding between the organic target on the cell surface and said cell scaffold material. Non-bound sample is removed under suitable conditions to maintain selective binding between the cell scaffold material and the organic target. This method results in cells exhibiting the organic target being immobilized to the cell scaffold material, and specifically to the protein structure, according to the invention.

As set out above, the cell scaffold material can be utilized to capture cells either directly or indirectly. In direct capture, the **B** moiety is capable of selective interaction with an organic target that is present on the cell surface. Alternatively, the **B** moiety is capable of selective interaction with and is bound to an intermediate organic target, and that intermediate organic target is capable of selective interaction with an organic target that is present on the cell surface. Thus, in indirect capture, the cell scaffold material is further comprising an intermediate organic target, and the **B** moiety is capable of selective interaction with and is bound to said intermediate organic target. The intermediate organic target, in turn, is capable of selective interaction with the organic target that is present on the cell surface.

Regardless of capture method, the captured cells may be released from the fusion protein by cleavage of the fusion protein to release the moiety involved in cell capture from the cell scaffold material. As mentioned hereinabove, the fusion protein may include a cleavage site in its amino acid sequence, which allows for cleavage and removal of the relevant moiety, typically the **B** moiety or a cell-binding motif. Various cleavage sites are known to the person skilled in the art, e.g. cleavage sites for chemical agents, such as CNBr after Met residues and hydroxylamine between Asn-Gly residues, cleavage sites for proteases, such as thrombin or protease 3C, and self-splicing sequences, such as intein self-splicing sequences.

The present invention also provides a method for cultivation of cells. Cells of interest are immobilized to the cell scaffold material using the method disclosed hereinabove. The combination of the cell scaffold material and the immobilized cells are maintained under conditions suitable for cell culture.

In the context of the present invention, the terms “cultivation” of cells, “cell culture” etc are to be interpreted broadly, such that they encompass for example situations in which cells divide and/or proliferate, situations in which cells are maintained in a differentiated state with retention of at least one functional characteristic exhibited by the cell type when present in its natural environment, and situations in which stem cells are maintained in an undifferentiated state.

The present invention will in the following be further illustrated by the following non-limiting examples.

Examples

Example 1 - Cloning, expression and fiber formation of ScFv-Rep_4CT fusion proteins

To prove the fusion protein concept, a Rep_4CT protein (a **REP** moiety with 4 internal repeats and a **CT** moiety) was produced in fusion with the single chain fragment variable (ScFv) (a **B** moiety). ScFv consist of VH and VL joined genetically together via a flexible polypeptide linker. This is the smallest (27kDa) entity with intact antigen binding capacity. The aim was to investigate whether it is possible to produce structures, such as fibers, films and membranes, from a fusion protein consisting of the ScFv fused to Rep_4CT and still retain the antigen-binding ability of ScFv, as well as the structure forming properties of Rep_4CT. In order to do so one fusion protein consisting of the ScFv N-terminally and one C-terminally to Rep_4CT was cloned.

Cloning

Genes (SEQ ID NOS: 59-60) encoding the $His_6ScFvRep_4CT$ and $His_6Rep_4CTScFv$ fusion proteins (SEQ ID NOS: 61-62) were constructed. The vectors were transformed into chemocompetent *Escherichia coli* (*E. coli*) BL21 (DE3) cells that were allowed to grow onto agar plates supplemented with kanamycin (70 µg/ml). Colonies were thereafter picked and PCR screened for correct insert and subsequently also sequenced to confirm the DNA sequence.

Production

E. coli BL21 (DE3) cells possessing the $pT7His_6ScFvRep_4CT$ or $pT7His_6ScFvRep_4CT$ vector were grown in Luria-Bertani medium (6 litre in total) supplemented with kanamycin (70 µg/ml) to an OD_{600} value of 1-1.5 in 30°C, followed by induction of expression with 300 µM IPTG (isopropyl β-D-1-thiogalactopyranoside) and further incubation in 20ºC for approximately 2 h. Next, the cells were harvested by a 20 min centrifugation at 4 700 rpm, and the resulting cell pellets were dissolved in 20 mM Tris (pH 8.0).

Purification

Cell pellets dissolved in 20 mM Tris (pH 8.0) were supplemented with lysozyme and DNase I in order to lyse the bacterial cells, whereupon the cell lysates were recovered after 15 000 rpm of centrifugation for 30 min. Next, the recovered cell lysates were divided and loaded onto a total of four Chelating Sepharose Fast Flow Zn^{2+} columns, keeping the protein bound to the column matrix via the His_6 tag. After washing, bound proteins were eluted with 20 mM Tris/300 mM imidazole (pH 8.0). Next, the pooled eluate liquid was dialysed against 5 litres of 20 mM Tris (pH 8.0) over night, concentrated to 1 mg/ml and finally allowed to form fibers or films.

The fact that macroscopic fibers of $His_6ScFvRep_4CT$ as well as $His_6Rep_4CTScFv$ could be obtained although Rep_4CT has been fused to another protein, i.e. the 27kDa ScFv, demonstrates that Rep_4CT still retains its fiber forming properties despite fused to ScFv.

Analysis of binding to ScFv

Two different methods were used for detection of antigen binding to the ScFv alone or in fusions with Rep_4CT: A) Direct addition of a Alexa647-labelled antigen, wash, and subsequent fluorescence measurement. B) Addition of biotynilated serum samples, wash, addition of Alexa647-labelled steptavidin, wash, and subsequent fluorescence measurements.

Results

Both $ScFvRep_4CT$ and $Rep_4CTScFv$ could be expressed, purified and assembled into films or fibers. All following experiments were done on films. Analysis of antigen binding using direct addition of Alex647-labelled antigen showed that both ScFv4repCT and 4RepCTScFv gave more intense spots, and thus bound more antigen than ScFv did when alone (Fig.3A). The intensity of the spots were measured at different detection intensities and ploted in figure 3B.

Figure 3 shows analysis of binding of Alexa647-labelled antigen:
A) Fluorographs of spots with bound antigen. The whiter dots, the more antigen.
B) Measurements of the intensity of the dots, using different detection intensities.

Analysis of biotinylated antigen from serum samples and subsequent steptavin binding showed that both $ScFvRep_4CT$ and $Rep_4CTScFv$ gave more intense spots, and thus bound more antigen than ScFv alone (Fig.4). However, unspecific binding to spots with only Rep_4CT can also be seen, although giving much lower signal than $ScFvRep_4CT$ and $Rep_4CTScFv$. This could be due to unspecific binding of either something else in the serum (e.g. albumin) or streptavidin.

Figure 4 shows analysis of binding of biotinylated antigen detected with Alexa647-labelled streptavidin. A) Fluorographs of spots with bound antigen and streptavidin. The whiter dots the more antigen. B) Measurements of the intensity of the dots, using different detection intensities.

Conclusions

Films spotted from ScFv fusions with Rep_4CT proteins bind >10 times more pure antigen compared to ScFv alone. However, if a biotinylated serum sample is analyzed with fluorophore labeled streptavidin, there are some unspecific binding (approx. 5 times lower) to Rep_4CT films that does not contain ScFv.

Example 2 - Cloning, expression and fiber formation of ScFv-CT fusion proteins

To prove the fusion protein concept, a CT protein (a **CT** moiety) is produced in fusion with the single chain fragment variable (ScFv) (a **B** moiety). The aim is to investigate whether it is possible to produce structures, such as fibers, films and membranes, from a fusion protein consisting of the ScFv fused to CT and still retain the antigen-binding ability of ScFv, as well as the structure forming properties of CT. In order to do so one fusion protein consisting of the ScFv N-terminally and one C-terminally to CT is cloned.

Cloning

Genes encoding the His_6ScFvCT and His_6CTScFv fusion proteins (SEQ ID NOS: 63-64) are constructed. The vectors are transformed into chemocompetent *E. coli* BL21 (DE3) cells that are allowed to grow onto agar plates supplemented with kanamycin (70 µg/ml). Colonies are thereafter picked and PCR screened for correct insert and subsequently also sequenced to confirm the DNA sequence.

Production

E. coli BL21 (DE3) cells possessing the pT7His_6ScFvCT or pT7His_6ScFvCT vector are grown in Luria-Bertani medium (6 litre in total) supplemented with kanamycin (70 µg/ml) to an OD_{600} value of 1-1.5 in 30°C, followed by induction of expression with 300 µM IPTG and further incubation in 20ºC for approximately 2 h. Next, the cells are harvested by a 20 min centrifugation at 4 700 rpm, and the resulting cell pellets are dissolved in 20 mM Tris (pH 8.0).

Purification

Cell pellets dissolved in 20 mM Tris (pH 8.0) are supplemented with lysozyme and DNase I in order to lyse the bacterial cells, whereupon the cell lysates are recovered after 15 000 rpm of centrifugation for 30 min. Next, the recovered cell lysates are divided and loaded onto a total of four Chelating Sepharose Fast Flow Zn^{2+} columns, keeping the protein bound to the column matrix via the His_6 tag. After washing, bound proteins are eluted with 20 mM Tris/300 mM imidazole (pH 8.0). Next, the pooled eluate liquid is dialysed against 5 litres of 20 mM Tris (pH 8.0) over night, concentrated to 1 mg/ml and finally allowed to form fibers or films.

Analysis of binding to ScFv

Two different methods are used for detection of antigen binding to the ScFv alone or in fusions with CT: A) Direct addition of a Alexa647-labelled antigen, wash, and subsequent fluorescence measurement. B) Addition of biotinylated serum samples, wash, addition of Alexa647-labelled steptavidin, wash, and subsequent fluorescence measurements.

Example 3 - Cloning, expression and fiber formation of ScFv-NTCT fusion proteins

To prove the fusion protein concept, a NT-CT protein (a **NT** and a **CT** moiety) is produced in fusion with the single chain fragment variable (ScFv) (a **B** moiety). The aim is to investigate whether it is possible to produce structures, such as fibers, films and membranes, from a fusion protein consisting of the ScFv fused to NT-CT and still retain the antigen-binding ability of ScFv, as well as the structure forming properties of NT-CT. In order to do so one fusion protein consisting of the ScFv N-terminally and one C-terminally to NTCT is cloned.

Cloning

Genes encoding the His_6ScFvNT-CT and His_6NT-CTScFv fusion proteins (SEQ ID NOS: 65-66) are constructed. The vectors were transformed into chemocompetent *E. coli* BL21 (DE3) cells that are allowed to grow onto

agar plates supplemented with kanamycin (70 µg/ml). Colonies are thereafter picked and PCR screened for correct insert and subsequently also sequenced to confirm the DNA sequence.

Production

E. coli BL21 (DE3) cells possessing the pT7His_6ScFvNT-CT or pT7His_6ScFvNT-CT vector are grown in Luria-Bertani medium (6 litre in total) supplemented with kanamycin (70 µg/ml) to an OD_{600} value of 1-1.5 in 30°C, followed by induction of expression with 300 µM IPTG and further incubation in 20ºC for approximately 2 h. Next, the cells are harvested by a 20 min centrifugation at 4 700 rpm, and the resulting cell pellets are dissolved in 20 mM Tris (pH 8.0).

Purification

Cell pellets dissolved in 20 mM Tris (pH 8.0) are supplemented with lysozyme and DNase I in order to lyse the bacterial cells, whereupon the cell lysates were recovered after 15 000 rpm of centrifugation for 30 min. Next, the recovered cell lysates were divided and loaded onto a total of four Chelating Sepharose Fast Flow Zn^{2+} columns, keeping the protein bound to the column matrix via the His_6 tag. After washing, bound proteins are eluted with 20 mM Tris/300 mM imidazole (pH 8.0). Next, the pooled eluate liquid is dialysed against 5 litres of 20 mM Tris (pH 8.0) over night, concentrated to 1 mg/ml and finally allowed to form fibers or films.

Analysis of binding to ScFv

Two different methods are used for detection of antigen binding to the ScFv alone or in fusions with NTCT: A) Direct addition of a Alexa647-labelled antigen, wash, and subsequent fluorescence measurement. B) Addition of biotynilated serum samples, wash, addition of Alexa647-labelled steptavidin, wash, and subsequent fluorescence measurements.

Example 4 - Cloning, expression and fiber formation of ScFv-NTRep$_4$CT fusion proteins

To prove the fusion protein concept, a NTRep$_4$CT protein (a **NT,** a **REP** moiety with 4 internal repeats and a **CT** moiety) is produced in fusion with the single chain fragment variable (ScFv) (a **B** moiety). The aim is to investigate whether it is possible to produce structures, such as fibers, films and membranes, from a fusion protein consisting of the ScFv fused to NT-CT and still retain the antigen-binding ability of ScFv, as well as the structure forming properties of NTRep$_4$CT. In order to do so one fusion protein consisting of the ScFv N-terminally and one C-terminally to NTRep$_4$CT is cloned.

Cloning

Genes encoding the His$_6$ScFvNTRep$_4$CT and His$_6$NTRep$_4$CTScFv fusion proteins (SEQ ID NOS: 67-68) are constructed. The vectors are transformed into chemocompetent *E. coli* BL21 (DE3) cells that are allowed to grow onto agar plates supplemented with kanamycin (70 µg/ml). Colonies are thereafter picked and PCR screened for correct insert and subsequently also sequenced to confirm the DNA sequence.

Production

E. coli BL21 (DE3) cells possessing the pT7His$_6$ScFvNTRep$_4$CT or pT7His$_6$ScFvNTRep$_4$CT vector are grown in Luria-Bertani medium (6 litre in total) supplemented with kanamycin (70 µg/ml) to an OD_{600} value of 1-1.5 in 30°C, followed by induction of expression with 300 µM IPTG and further incubation in 20ºC for approximately 2 h. Next, the cells are harvested by a 20 min centrifugation at 4 700 rpm, and the resulting cell pellets are dissolved in 20 mM Tris (pH 8.0).

Purification

Cell pellets dissolved in 20 mM Tris (pH 8.0) are supplemented with lysozyme and DNase I in order to lyse the bacterial cells, whereupon the cell lysates are recovered after 15 000 rpm of centrifugation for 30 min. Next, the recovered cell lysates are divided and loaded onto a total of four Chelating

Sepharose Fast Flow Zn^{2+} columns, keeping the protein bound to the column matrix via the His_6 tag. After washing, bound proteins are eluted with 20 mM Tris/300 mM imidazole (pH 8.0). Next, the pooled eluate liquid is dialysed against 5 litres of 20 mM Tris (pH 8.0) over night, concentrated to 1 mg/ml and finally allowed to form fibers or films.

Analysis of binding to ScFv

Two different methods are used for detection of antigen binding to the ScFv alone or in fusions with $NTRep_4CT$: A) Direct addition of a Alexa647-labelled antigen, wash, and subsequent fluorescence measurement. B) Addition of biotynilated serum samples, wash, addition of Alexa647-labelled steptavidin, wash, and subsequent fluorescence measurements.

Example 5 - Cloning, expression and fiber formation of ScFv-NTNTCT fusion proteins

To prove the fusion protein concept, a NTNT-CT protein (two **NT** and one **CT** moieties) is produced in fusion with the single chain fragment variable (ScFv) (a **B** moiety). The aim is to investigate whether it is possible to produce structures, such as fibers, films and membranes, from a fusion protein consisting of the ScFv fused to NT-CT and still retain the antigen-binding ability of ScFv, as well as the structure forming properties of NT-CT. In order to do so one fusion protein consisting of the ScFv N-terminally and one C-terminally to NTNTCT is cloned.

Cloning

Genes encoding the His_6ScFvNTNT-CT and His_6NTNT-CTScFv fusion proteins (SEQ ID NOS: 69-70) are constructed. The vectors are transformed into chemocompetent *E. coli* BL21 (DE3) cells that are allowed to grow onto agar plates supplemented with kanamycin (70 µg/ml). Colonies are thereafter picked and PCR screened for correct insert and subsequently also sequenced to confirm the DNA sequence.

Production

E. coli BL21 (DE3) cells possessing the pT7His$_6$ScFvNTNT-CT or pT7His$_6$ScFvNTNT-CT vector are grown in Luria-Bertani medium (6 litre in total) supplemented with kanamycin (70 µg/ml) to an OD_{600} value of 1-1.5 in 30°C, followed by induction of expression with 300 µM IPTG (isopropyl β-D-1-thiogalactopyranoside) and further incubation in 20ºC for approximately 2 h. Next, the cells are harvested by a 20 min centrifugation at 4 700 rpm, and the resulting cell pellets are dissolved in 20 mM Tris (pH 8.0).

Purification

Cell pellets dissolved in 20 mM Tris (pH 8.0) are supplemented with lysozyme and DNase I in order to lyse the bacterial cells, whereupon the cell lysates are recovered after 15 000 rpm of centrifugation for 30 min. Next, the recovered cell lysates are divided and loaded onto a total of four Chelating Sepharose Fast Flow Zn^{2+} columns, keeping the protein bound to the column matrix via the His_6 tag. After washing, bound proteins are eluted with 20 mM Tris/300 mM imidazole (pH 8.0). Next, the pooled eluate liquid is dialysed against 5 litres of 20 mM Tris (pH 8.0) over night, concentrated to 1 mg/ml and finally allowed to form fibers or films.

Analysis of binding to ScFv

Two different methods are used for detection of antigen binding to the ScFv alone or in fusions with NTNT-CT: A) Direct addition of a Alexa647-labelled antigen, wash, and subsequent fluorescence measurement. B) Addition of biotynilated serum samples, wash, addition of Alexa647-labelled steptavidin, wash, and subsequent fluorescence measurements.

Example 6 - Cloning, expression and formation of structures of scFv1-NTCT and scFv1-CT fusion proteins

NTCT and CT were produced in fusion with an engineered antibody fragment named single chain fragment variable 1 (scFv1). scFv1 is a 27-kDa monovalent, engineered antibody fragment that recognizes the antigens specific for an autoimmune disease, Systemic Lupus Erythematosus (SLE).

Our aim was to investigate whether it is possible to produce structures, such as fibers and films, from the fusion proteins consisting of the scFv1 protein domain fused to NTCT (denoted His_6-scFv1-NTCT, SEQ ID NO: 72) and to CT (denoted His_6-scFv1-CT, SEQ ID NO: 74) respectively, and still retain the antigen detection ability of scFv1 domain as well as the structure forming properties of NTCT and CT. In order to do so, two fusion proteins consisting of the scFv1 domain fused N-terminally to NTCT and to CT were cloned.

Cloning

A gene (SEQ ID NO: 73) encoding the His_6-scFv1-CT fusion protein (SEQ ID NO: 74) was constructed as follows. Primers were designed in order to generate PCR fragments of domain scFv1 from a vector containing such a scFv1 sequence. Also, the primers contained recognition sites for the restriction endonucleases *NdeI* and *EcoRI*. The resulting PCR products were then treated with the restriction endonucleases *NdeI* and *EcoRI*, as was the target vector (denoted pAff8His_6TrxHis_6CT, harbouring a kanamycin resistance gene). Upon restriction cleavage of the target vector, the His_6TrxHis_6 part was cleaved off. Cleaved PCR fragments and target vector were joined together with the aid of a T4 DNA Ligase, whereupon the resulting correctly ligated vector (pT7His_6-scFv1-CT) was transformed into chemocompetent *E. coli* BL21 (DE3) cells that were allowed to grow onto agar plates supplemented with kanamycin (50 µg /ml). Colonies were thereafter picked and screened for correct insert and subsequently also sequenced to confirm the DNA sequence of inserted scFv1 into the target vector.

Cloning of a gene (SEQ ID NO: 71) encoding the His_6-scFv1-NTCT fusion protein (SEQ ID NO: 72) was performed in the same way as described for His_6-scFv1-CT, but the primers used for the amplification of NTCT contained sites for the restriction endonucleases *EcoRI* and *HindIII* and the target vector here was denoted by pT7His_6scFv1-RepCT, where the RepCT part was cleaved off upon treatment with *EcoRI* and *HindIII*. The correctly ligated vector is denoted as pT7His_6scFv1-NTCT.

Production

E. coli BL21 (DE3) cells possessing the pT7His$_6$-scFv1-CT vector were grown in Luria-Bertani medium (3 liters in total) supplemented with kanamycin (50 µg/ml) to an OD_{600} value of 1-1.5 in 30°C, followed by induction of pT7His$_6$-scFv1-CT expression with 300 µM IPTG and further incubation at14ºC for approximately 17 h. Next, the cells were harvested by a 20 min centrifugation at 4 700 rpm, and the resulting cell pellet was dissolved in 20 mM Tris (pH 8.0).

Production of pT7His$_6$-scFv1-NTCT was performed in the same way as described for pT7His$_6$-scFv1-CT except for the total volume of the culture media used (6 liters) in its production.

Purification

The cell pellet dissolved in 20 mM Tris (pH 8.0) was supplemented with lysozyme and DNase I in order to lyse the bacterial cells, followed by the addition of NaCl and imidazole to a final concentration of 200 mM and 10 mM, respectively. After 30 min of centrifugation (15 000 rpm) the cell lysate was recovered. Next, the recovered cell lysate was loaded onto a Chelating Sepharose Fast Flow Zn^{2+} column, keeping the His$_6$-scFv1-CT (SEQ ID NO: 74) protein bound to the column matrix via the His$_6$ tag. After washing, bound proteins were eluted with 20 mM Tris/200 mM imidazole (pH 8.0)/300 mM NaCl. The eluate contained 0.93 mg of His$_6$-scFv1-CT protein according to an A_{280} measurement. Next, the eluted protein was dialyzed against 3 liters of 20 mM Tris (pH 8.0) over night and thereafter concentrated to 0.87 mg/ml, yielding a final amount of 0.348 mg His$_6$-scFv1-CT fusion protein (SEQ ID NO: 74).

The same purification procedure was carried out for His$_6$-scFv1-NTCT (SEQ ID NO: 72), whose eluate contained 4.86 mg of fusion protein. After protein concentration to 2.14 mg/ml, a final amount of 2.57 mg His$_6$-scFv1-NTCT was obtained.

Film, foam and fiber formation

Films of His_6-scFv1-CT were spotted onto microarray slides (plastic MaxiSorp, Nunc) from 1 µl of 5 µM soluble fusion protein per film. The films were then allowed to solidify over night in a climate controlled room. The same procedure was followed for casting films of His_6-scFv1-NTCT from 1 µl of 5 µM protein solution.

Fiber was made for His_6-scFv1-NTCT from 0.49 mg/ml (data not shown) and foams were made for both His_6-scFv1-NTCT and His_6-scFv1-CT from 30 µl of 0.22 and 0.38 mg/ml of soluble fusion protein, respectively (Fig-5a and 5b). The fact that macroscopic fiber and foam for His6-scFv1-NTCT and His6-scFv1-CT respectively, could be obtained although NTCT or CT has been fused to another protein, i.e. the 263 amino acids long scFv1 domain, demonstrates that NTCT and CT still retains there structure forming properties despite fused to the scFv1 domain.

Analysis

Pure antibody (scFv1, control) and silk fused antibody (scFv1-NTCT) were spotted in the microarray format manually by adding 1 µL of 5 µM protein solution onto clear and black polymer MaxiSorp microarray slides (NUNC, 25x76 mm) resulting in 135 pmoles of pure antibody (scFv1) and 274 pmoles of silk fused antibody (scFv1-NTCT) in the spotted films, respectively. After spotting the proteins in film format, the films were dried overnight in a climate controlled room. The arrays were then blocked by applying 200 µl of sample buffer (1% (w/v) fat-free milk powder and 1% (v/v) Tween-20 in PBS) for 90 min and then washed three times by applying 200-300 µl of wash buffer (0.05% (v/v) Tween-20 in PBS). All incubations were performed at room temperature on gentle agitation. Next, 100-200 µl of biotinylated antigen sample (10 nM) diluted in sample buffer was applied and incubated for 1h. The arrays were then washed three times by applying 200-300 µl of wash buffer and to detect the bound antigens, 100-200 µl of Alexa-647-labeled streptavidin (1 µg/ml) diluted in sample buffer, was applied onto the arrays and incubated for 1 h. Finally, the arrays were washed three times with 200-300 µl of wash buffer and dried under a stream of nitrogen gas. The arrays were then scanned using a confocal microarray fluorescence scanner (ScanArray Express, Perkin-Elmer Life & Analytical Sciences). The ScanArray Express software V2.0 (Perkin-Elmer Life & Analytical Sciences)

was used to quantify the intensity of each spot. The same analysis procedure was carried out for analyzing His6-scFv1-CT fusion protein.

In order to detect the low abundant serum proteins which can be of potential biomarkers, scFv1 was fused to N-terminal of NTCT or CT giving rise to His_6-scFv1-NTCT and His_6-scFv1-CT, respectively. Pure antibody (control) and silk fused antibody fragments were spotted onto the microarray slide and their antigen binding capacity was analyzed using biotinylated antigen sample. Alexa-647-labeled streptavidin was then used to detect the bound antigens. Fig. 6 shows an antigen binding analysis of pure (control) and silk fused antibody fragments. Intensity of the spots was measured at 5090 detection intensity. The analysis showed that the antigen recognition of silk fused antibody (His_6-scFv1-NTCT) fragment was increased by 25 times compared to the scFv1 control alone, and no sign of cross reactivity with other antigens was observed for His_6-scFv1-NTCT.

CLAIMS

1. A recombinant fusion protein comprising the moieties **B** and **CT**, and optionally **REP**, wherein:

B is comprising at least one immunoglobulin fragment, which provides the capacity of selective interaction with an organic target;

CT is a moiety of from 70 to 120 amino acid residues and is derived from the C-terminal fragment of a spider silk protein; and

REP is a moiety of from 70 to 300 amino acid residues and is derived from the repetitive fragment of a spider silk protein.

2. A recombinant fusion protein according to claim 1, wherein each immunoglobulin fragment of the **B** moiety is selected from immunoglobulin variable regions.

3. A recombinant fusion protein according to any preceding claim, wherein the **B** moiety is comprising at least one heavy chain variable region (V_H) and at least one light chain variable region (V_L).

4. A recombinant fusion protein according to any preceding claim, wherein the **B** moiety is selected from the group consisting of single-chain variable fragments (scFv fragments), fragment antigen-binding (Fab fragments), $F(ab')_2$ fragments, domain antibodies (dAbs) and single domain antibodies (sdABs).

5. A recombinant fusion protein according to claim 4, wherein the **B** moiety is a single-chain variable fragment (scFv).

6. A recombinant fusion protein according to any preceding claim, wherein the **B** moiety contains 30-1000 amino acid residues, such as 150-400 amino acid residues.

7. A recombinant fusion protein according to any preceding claim, wherein the **CT** moiety has at least 50% identity to SEQ ID NO: 9 or at least 80% identity to SEQ ID NO: 7.

8. A recombinant fusion protein according to any preceding claim, selected from the group of proteins defined by the formulas
B_x-CT-B_z, **B_x-REP-B_y-CT-B_z** and **B_x-CT-B_y-REP-B_z**,
wherein x, y and z are integers from 0 to 5;
and $x+y+z \geq 1$.

9. A recombinant fusion protein according to claim 8, selected from the group of proteins defined by the formulas **B_x-CT**, **CT-B_z**, **B_x-REP-CT**, **B_x-CT-REP**, **REP-CT-B_z** and **CT-REP-B_z**;
wherein x and z are integers from 1 to 5.

10. A recombinant fusion protein according to claim 9, selected from the group of proteins defined by the formulas **B-CT**, **CT-B**, **B-REP-CT**, **B-CT-REP**, **REP-CT-B** and **CT-REP-B**.

11. A recombinant fusion protein according to any previous claim, wherein the **REP** moiety is selected from the group of **L$(AG)_n$L**, **L$(AG)_n$AL**, **L$(GA)_n$L**, **L$(GA)_n$GL**, wherein

n is an integer from 2 to 10;

each individual **A** segment is an amino acid sequence of from 8 to 18 amino acid residues, wherein from 0 to 3 of the amino acid residues are not Ala, and the remaining amino acid residues are Ala;

each individual **G** segment is an amino acid sequence of from 12 to 30 amino acid residues, wherein at least 40% of the amino acid residues are Gly; and

each individual **L** segment is a linker amino acid sequence of from 0 to 20 amino acid residues.

12. A recombinant fusion protein according to any previous claim, selected from the group consisting of SEQ ID NOS: 61-70; and proteins having at least 80% identity to any of these sequences.

13. An isolated nucleic acid encoding a fusion protein according to any one of claims 1-12.

14. An isolated nucleic acid according to claim 13, selected from the group consisting of nucleic acids encoding a fusion protein according to claim 12 and the group consisting of SEQ ID NOS: 59-60.

15. A protein structure capable of selective interaction with an organic target, wherein said protein structure is a polymer comprising as a repeating structural unit a recombinant fusion protein according to any one of claims 1-12, wherein the **B** moiety provides the capacity of selective interaction with the organic target.

16. A protein structure according to claim 15, wherein said protein structure has a size of at least 0.1 µm in at least two dimensions.

17. A protein structure according to any one of claims 15-16, wherein said protein structure is in a physical form selected from the group consisting of fiber, film, foam, net, mesh, sphere and capsule.

18. Use of a recombinant fusion protein according to any one of claims 1-12 for production of a protein structure capable of selective interaction with an organic target, wherein said protein structure is a polymer comprising as a repeating structural unit the recombinant fusion protein, and wherein the **B** moiety provides the capacity of selective interaction with the organic target.

19. Use of a protein structure according to any one of claims 15-17 in separation of an organic target from a sample.

20. Use of a protein structure according to any one of claims 15-17 in cultivation of cells.

21. A method of producing a fusion protein, comprising the following steps:

a) expressing in a suitable host a fusion protein according to any one of claims 1-12; and

b) obtaining a mixture containing the fusion protein, and optionally isolating the fusion protein.

22. A method for providing a protein structure according to any one of claims 15-17, displaying a binding activity towards an organic target, comprising the steps of:

(a) providing a recombinant fusion protein according to any one of claims 1-12;

(b) subjecting the fusion protein to conditions to achieve formation of a polymer comprising the recombinant fusion protein.

23. An affinity medium for immobilization of an organic target, said affinity medium comprising a fusion protein according to any one of claims 1-12, wherein the **B** moiety is capable of selective interaction with the organic target.

24. An affinity medium according to claim 23, said affinity medium comprising a protein structure according to any one of claims 15-17, which protein structure is a polymer comprising the recombinant fusion protein.

25. An affinity medium according to any one of claims 23-24, further comprising said organic target, wherein the **B** moiety is capable of selective interaction with and is bound to said organic target.

26. An affinity medium according to claim 25, wherein said organic target is capable of selective interaction with a second organic target.

27. A cell scaffold material for cultivation of cells having an organic target that is present on the cell surface, said cell scaffold material comprising a protein structure according to any one of claims 15-17.

28. A cell scaffold material according to claim 27, wherein the **B** moiety is capable of selective interaction with the organic target that is present on the cell surface.

29. A cell scaffold material according to claim 27, wherein said cell scaffold material is further comprising an intermediate organic target, wherein the **B** moiety is capable of selective interaction with and is bound to said intermediate organic target, and wherein said intermediate organic target is capable of selective interaction with the organic target that is present on the cell surface.

30. A combination of cells and a cell scaffold material according to any one of claims 27-29.

31. A method for separation of an organic target from a sample, comprising the steps of:

providing a sample containing the organic target;

providing an affinity medium according to any one of claims 23-26, wherein said affinity medium is capable of selective interaction with the organic target;

contacting said affinity medium with said sample under suitable conditions to achieve binding between the affinity medium and the organic target; and

removing non-bound sample.

32. A method according to claim 31, further comprising the step of contacting said affinity medium and the immobilized organic target with a second organic target, which is capable of selective interaction with the first organic target,

under suitable conditions to achieve binding between the first and second organic targets.

33. A method according to any one of claims 31-32, wherein the fusion protein in the affinity medium is present as a protein structure according to any one of claims 15-17 when contacting said affinity medium with said sample to achieve binding between the affinity medium and the organic target.

34. A method according to any one of claims 31-32, wherein the fusion protein in the affinity medium is present in solution when contacting said affinity medium with said sample to achieve binding between the affinity medium and the organic target, and wherein the complex of fusion protein bound to the organic target is allowed to form a fusion protein structure according to any one of claims 15-17.

35. A method according to any one of claims 31-34, further comprising the step of detecting, and optionally quantifying, the presence of the immobilized target on said affinity medium.

36. A method according to any one of claims 31-35, further comprising the step of releasing and collecting the organic target from the affinity medium.

37. A method according to any one of claims 31-36, further comprising the final step of regenerating the affinity medium by chemical treatment and/or sterilizing heat treatment.

38. A method according to claim 37, wherein the chemical treatment comprises treatment with NaOH and/or urea.

39. A method for immobilization of cells, comprising

providing a sample comprising cells of interest;

applying said sample to a cell scaffold material according to any one of claims 27-29, wherein said cell scaffold material is capable of selective interaction with an organic target that is present on the cell surface; and

allowing said cells to immobilize to said cell scaffold material by binding between the organic target on the cell surface and said cell scaffold material.

40. A method for cultivation of cells, comprising

immobilizing cells of interest to a cell scaffold material according to the method of claim 39; and

maintaining said cell scaffold material having cells applied thereto under conditions suitable for cell culture.

```
CThyb_Esp       SRLSSPEASS RVSSAVSNLV SSG-PTNSAA LSSTISNVVS QIGASNPGLS
CTnat_Eau       SRLSSPSAVS RVSSAVSSLV SNG-QVNMAA LPNIISNISS SVSASAPGAS
AF350266_At1    SRLSSPGAAS RVSSAVTSLV SSGGPTNSAA LSNTISNVVS QISSSNPGLS
AY666062_Cm1    SHLSSPEASS RVSSAVSNLV SSG-STNSAA LPNTISNVVS QISSSNPGLS
AF350273_Lg1    SALAAPATSA RISSHASTLL SNG-PTNPAS ISNVISNAVS QISSSNPGAS
AY953074_Lh1    SALSAPATSA RISSHASALL SSG-PTNPAS ISNVISNAVS QISSSNPGAS
AY666068_Mh1    SHLSSPEASS RVSSAVSNLV SGG-STNSAA LPNTISNVVS QISSSNPGLS
U20329_Nc1      SRLSSPQASS RVSSAVSNLV ASG-PTNSAA LSSTISNVVS QIGASNPGLS
AY666076_Np1    SRLSSPEASS RVSSAVSNLV SSG-PTNSAA LSNTISNVVS QISSSNPGLS
AF350277_Nm1    SRLSSPQASS RVSSAVSNLV ASG-PTNSAA LSSTISNAVS QIGASNPGLS
AF350279_Ns1    SRLSSPEASS RVSSAVSNLV SSG-PTNSAA LSSTISNVVS QIGASNPGLS
AY666057_Ov1    SRLSSPEASS RVSSAVSNLV SSG-PTNSAA LSNTISNVVS QISSSNPGLS
AY666064_Ps1    SRLSSPEASS RVSSAVSNLV SSG-PTNSAA LPNTISNVVS QISSSNPGLS
AF350285_Tk1    SLLSSPASNA RISSAVSALA SGA-ASGPGY LSSVISNVVS QVSSNSGGLV
AF350286_Tv1    SRLSSPASNA RISSAVSALA SGG-ASSPGY LSSIISNVVS QVSSNNDGLS
ABU20328_Ab2    SRLSSSAASS RVSSAVSSLV SSG-PTTPAA LSNTISSAVS QISASNPGLS
AY365016_Aam2   -RLSSPQASS RVSSAVSTLV SSG-PTNPAS LSNAIGSVVS QVSASNPGLP
AF350263_Aau2   SRLSSPQASS RVSSAVSTLV SSG-PTNPAA LSNAISSVVS QVSASNPGLS
AF350267_At2    SRLSSPQASS RVSSAVSTLV SSG-PTNPAS LSNAISSVVS QVSSSNPGLS
AF350272_Gm2    SRLSSPQAGA RVSSAVSALV ASG-PTSPAA VSSAISNVAS QISASNPGLS
AF350275_Lg2    SALSSPTTHA RISSHASTLL SSG-PTNSAA ISNVISNAVS QVSASNPGSS
AY953075_Lh2    SALSSPTTHA RISSHASTLL SSG-PTNAAA LSNVISNAVS QVSASNPGSS
AY654293_Nc2    SRLASPDSGA RVASAVSNLV SSG-PTSSAA LSSVISNAVS QIGASNPGLS
AF350278_Nm2    SRLASPDSGA RVASAVSNLV SSG-PTSSAA LSSVISNAVS QIGASNPGLS
AF350280_Ns2    SRLASPDSGA RVASAVSNLV SSG-PTSSAA LSSVIXNAVS QIGASNPGLS
AF350269_DtFb1  SRLSSPEAAS RVSSAVSSLV SNG-QVNVDA LPSIISNLSS SISASATTAS
AF350270_DtFb2  SRLSSPQAAS RVSSAVSSLV SNG-QVNVAA LPSIISSLSS SISASSTAAS
U47853_ADF1     NRLSSAGAAS RVSSNVAAIA SAG----AAA LPNVISNIYS GVLSS--GVS
U47854_ADF2     SRLSSPSAAA RVSSAVS-LV SNGGPTSPAA LSSSISNVVS QISASNPGLS
U47855_ADF3     SRLSSPAASS RVSSAVSSLV SSG-PTKHAA LSNTISSVVS QVSASNPGLS
U47856_ADF4     SVYLRLQPRL EVSSAVSSLV SSG-PTNGAA VSGALNSLVS QISASNPGLS

Consensus       SRLSSPQASS RVSSAVSNLV SSG-PTNSAA LSNTISNVVS QISASNPGLS
```

Fig 1

```
CThyb_Esp       GCDVLVQALL EVVSALIHIL GSSSIGQVNY GSAGQATQLV GQSVYQALGE F
CTnat_Eau       GCEVIVQALL EVITALVQIV SSSSVGYINP SAVNQITNVV ANAMAQVMG- -
AF350266_At1    GCDVLVQALL EIVSALVHIL GSANIGQVNS SGVGRSASIV GQSINQAFS- -
AY666062_Cm1    GCDVLVQALL EVVSALIHIL GSSSIGQVNY GSAGQATQIV ---------- -
AF350273_Lg1    SCDVLVQALL ELVTALLTII GSSNVGNVNY DSSGQYAQVV SQSVQNAFV- -
AY953074_Lh1    ACDVLVQALL ELVTALLTII GSSNIGSVNY DSSGQYAQVV TQSVQNVFG- -
AY666068_Mh1    GCDVLVQALL EVVSALIHIL GSSSIGQVDY GSAGQATQIV GQSA------ -
U20329_Nc1      GCDVLIQALL EVVSALIQIL GSSSIGQVNY GSAGQATQIV GQSVYQALG- -
AY666076_Np1    GCDVLVQALL EVVSALIHIL GSSSIGQVNY GSAGQATQIV ---------- -
AF350277_Nm1    GCDVLIQALL EVVSALIHIL GSSSIGQVNY GSAGQATQ-- ---------- -
AF350279_Ns1    GCDVLIQALL EVVSALVHIL GSSSIGQVNY GSAGQATQ-- ---------- -
AY666057_Ov1    GCDVLVQALL EVVSAPIHIL GSSSIGQVNY GSAGQATQIV ---------- -
AY666064_Ps1    GCDVLVQALL EVVSALIHIL GSSSIGQVNY GSAGQATQIV ---------- -
AF350285_Tk1    GCDTLVQALL EAAAALVHVL ASSSGGQVNL NTAGYTSQL- ---------- -
AF350286_Tv1    GCDTVVQALL EVAAALVHVL ASSNIGQVNL NTAGYTSQL- ---------- -
ABU20328_Ab2    GCDVLVQALL EVVSALVHIL GSSSVGQINY GASAQYAQMV ---------- -
AY365016_Aam2   SCDVLVQALL EIVSALVHIL GSSSIGQINY SASSQYARLV GQSIAQALG- -
AF350263_Aau2   GCDVLVQALL ELVSALVHIL GSSSIGQINY AAS------- ---------- -
AF350267_At2    GCDVLVQALL EIVSALVHIL GSSSIGQINY AASSQYAQLV GQSLTQALG- -
AF350272_Gm2    GCDVLVQALL EIVSALVSIL SSASIGQINY GASGQYAAMI ---------- -
AF350275_Lg2    SCDVLVQALL ELITALISIV DSSNIGQVNY GSSGQYAQMV G--------- -
AY953075_Lh2    SCDVLVQALL EIITALISIL DSSSVGQVNY GSSGQYAQIV GQSMQQAMG- -
AY654293_Nc2    GCDVLIQALL EIVSACVTIL SSSSIGQVNY GAASQFAQVV GQSVLSAF-- -
AF350278_Nm2    GCDVLIQALL EIVSACVTIL SSSSIGQVNY GAA------- ---------- -
AF350280_Ns2    GCDVLIXALL EIVSACVTIL SSSSIGQVNY GAA------- ---------- -
AF350269_DtFb1  DCEVLVQVLL EVVSALVQIV CS-------- ---------- ---------- -
AF350270_DtFb2  DCEVLVQVLL EIVSALVQIV SSANVGYINP EASGSLN-AV GSALAAAMG- -
U47853_ADF1     SSEALIQALL EVISALIHVL GSASIGNVSS VGVNSALNAV QNAVGAYAG- -
U47854_ADF2     GCDILVQALL EIISALVHIL GSANIGPVNS SSAGQSASIV GQSVYRALS- -
U47855_ADF3     GCDVLVQALL EVVSALVSIL GSSSIGQINY GASAQYTQMV GQSVAQALA- -
U47856_ADF4     GCDALVQALL ELVSALVAIL SSASIGQVNV SSVSQSTQMI SQALS----- -

Consensus       GCDVLVQALL EVVSALVHIL GSSSIGQVNY GSAGQATQIV GQSVAQALGE F
```

Fig 1 (continued)

```
Ea MaSp1   SHTTPWTNPGLAENFMNSFMQGLSSMPGFTASQLDDMSTIAQSMVQSIQSLAAQGRTSPNKLQALNMAFA
Lg MaSp1   QANTPWSSKANADAFINSFISSAQNTGSFSQDQMDDMSLIGNTLMTAMDNMG--GRITPSKLQALDMAFA
Lh MaSp1   QANTPWSSKANADAFINSFISAASNTGSFSQDQMEDMSLIGNTLMAAMDNMG--GRITPSKLQALDMAFA
Nc MaSp1   -QNTPWSSTELADAFINAFMNEAGRTGAFTADQLDDMSTIGDTIKTAMDKMARSNKSSKGKLQALNMAFA
At MaSp2   QGATPWENSQLAESFISRFLRFIGQSGAFSPNQLDDMSSIGDTLKTAIEKMAQSRKSSKSKLQALNMAFA
Lg MaSp2   ---LRWSSKDNADRFINAFLQAASNSGAFSSDQVDDMSVIGNTLMTAMDNMG--GRITPSKLQALDMAFA
Lh MaSp2   QANTPWSSKENADAFIGAFMNAASQSGAFSSDQIDDMSVISNTLMAAMDNMG--GRITQSKLQALDMAFA
Nim MaSp2  QANTPWSDTATADAFIQNFLGAVSGSGAFTPDQLDDMSTVGDTIMSAMDKMARSNKSSKSKLQALNMAFA
Nc MaSp2   QARSPWSDTATADAFIQNFLAAVSGSGAFTSDQLDDMSTIGDTIMSAMDKMARSNKSSQHKLQALNMAFA
Ab CySp1   AVPSVFSSPNLASGFLQCLTFGIGNSPAFPTQEQQDLDAIAQVILNAVSSNTGATASAR--AQALSTALA
Ncl CySp1  PVPSVFSSPSLASGFLGCLTTGIGLSPAFPFQEQQDLDDLAKVILSAVTSNTDTSKSAR--AQALSTALA
Lh TuSp1   ASVNIFNSPNAATSFLNCLRSNIESSPAFPFQEQADLDSIAEVILSDVSS-VNTASSAT--SLALSTALA
Nc flag    IANSPFSNPNTAEAFARSFVSNIVSSGEFGAQGAEDFDDIIQSLIQAQ-SMGKGRHDTKAKAKAMQVALA
Nlm flag   IVNSPFSNPNTAEAFARSFVSNVVSSGEFGAQGAEDFDDIIQSLIQAQ-SMGKGRHDTKAKAKAMQVALA

Ea MaSp1   SSMAEIAASEEGGGSLSTKTSSIASAMSNAFLQTTGVVNQPFINEITQLVSMFAQAGMNDV
Lg MaSp1   SSVAEIAASEG--GDLGVTTNAIADALTSAFYQTTGVVNNRFISEIRSLISMFAQASANDV
Lh MaSp1   SSVAEIAASEG--GDLGVTTNAIADALTSAFYQTTGVVNSRFISEIRSLIGMFAQASANDV
Nc MaSp1   SSMAEIAAVEQGGLSVDAKTNAIADSLNSAFYQTTGAANPQFVNEIRSLINMFAQSSANEV
At MaSp2   SSMAEIAVAEQGGLSLEAKTNAIASALSAAFLETTGYVNQQFVNEIKTLIFMIAQASSNEI
Lg MaSp2   SSVAEIAVADG--QNVGGATNAISNALRSAFYQTTGVVNNQFISEISNLINMFAQVSANEV
Lh MaSp2   SSVAEIAVADG--QNVGAATNAISDALRSAFYQTTGVVNNQFITGISSLIGMFAQVSGNEV
Nim MaSp2  SSMAEIAAVEQGGQSMDVKTNAIANALDSAFYMTTGSTNQQFVNEMRSLINMLSAAAVNEV
Nc MaSp2   SSMAEIAAVEQGGMSMAVKTNAIVDGLNSAFYMTTGAANPQFVNEMRSLISMISAASANEV
Ab CySp1   SSLTDLLIAESAESNYSNQLSELTGILSDCFIQTTGSDNPAFVSRIQSLISVLSQNADTNI
Ncl CySp1  SSLADLLISESSGSSYQTQISALTNILSDCFVTTTGSNNPAFVSRVQTLIGVLSQSSSNAI
Lh TuSp1   SSLAELLVTESAEEDIDNQVVALSTILSQCFVETTGSPNPAFVASVKSLLGVLSQSASNYE
Nc flag    SSIAELVIAESSGGDVQRKTNVISNALRNALMSTTGSPNEEFVHEVQDLIQMLSQEQINEV
Nlm flag   SSIAELVIAESSGGDVQRKTNVISNALRNALMSTTGSPNEEFVHEVQDLIQMLSQEQINEV
```

Fig 2


A
3x ScFv4RepCT, 3x 4RepCTScFv
3x 4RepCT, 3x ScFv
3x ScFv4RepCT, 3x 4RepCTScFv
3x 4RepCT, 3x ScFv
Array 1
100 nM
antigen
Array 2
1 nM
antigen
B
Array 1
Array 2
ScFv-4RepCT
4RepCT-ScFv
4RepCT
ScFv
Fluorescence
Detection intensity
80000
60000
40000
20000
0
5050
7070
8080
9090

Fig 3


A
Array 1
100 nM
biotin-antigen
Array 2
10 nM
biotin-antigen
3x ScFv4RepCT, 3x 4RepCTScFv
3x 4RepCT, 3x ScFv
3x ScFv4RepCT, 3x 4RepCTScFv
3x 4RepCT, 3x ScFv
B
Array 1
Array 2
ScFv-4RepCT
4RepCT-ScFv
4RepCT
ScFv
Fluorescence
Detection intensity
80000
60000
40000
20000
0
5050
7070
8080
9090

Fig 4

a b



Fig 5


25000
20000
15000
10000
5000
0
Fluorescence at 5090 detection intensity
scFv1
scFv1-NTCT
Proteins spotted on the slide

Fig 6

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2013/059145

A. CLASSIFICATION OF SUBJECT MATTER
INV. B01D15/38 C07K14/435 C12N15/62 C07K14/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
B01D C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, BIOSIS, Sequence Search, EMBASE, FSTA, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MORGAN ET AL: "Characterization and optimization of RGD-containing silk blends to support osteoblastic differentiation", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 29, no. 16, 5 March 2008 (2008-03-05) , pages 2556-2563, XP022559053, ISSN: 0142-9612	15-40
A	the whole document	1-14

-/--

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
24 July 2013	31/07/2013

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Voigt-Ritzer, Heike

2

Form PCT/ISA/210 (second sheet) (April 2005)

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ANNA RISING ET AL: "Spider silk proteins: recent advances in recombinant production, structureâ function relationships and biomedical applications", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHÄUSER-VERLAG, BA, vol. 68, no. 2, 29 July 2010 (2010-07-29), pages 169-184, XP019871087, ISSN: 1420-9071, DOI: 10.1007/S00018-010-0462-Z cited in the application	15-40
A	table 3 page 175, column 2, paragraph 2 - page 179, column 1, paragraph 1 page 180, column 1, paragraph 2 - column 2, paragraph 1	1-14

X	WO 2005/111068 A2 (DU PONT [US]; HOFFMANN CHRISTIAN [US]; KELLER KARSTEN [US]) 24 November 2005 (2005-11-24)	1,6-11, 13,21
A	page 17, line 22 - line 25	2-5,12, 14-20, 22-40

X,P	WO 2012/055854 A1 (SPIBER TECHNOLOGIES AB [SE]; HEDHAMMAR MY [SE]; JOHANSSON JAN [SE]; RI) 3 May 2012 (2012-05-03) examples 1,2,7,24	1-12,21

A	HEDHAMMAR MY ET AL: "Structural properties of recombinant nonrepetitive and repetitive parts of major ampullate spidroin 1 from Euprosthenops australis: Implications for fiber formation", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 47, no. 11, 1 March 2008 (2008-03-01) , pages 3407-3417, XP002547535, ISSN: 0006-2960, DOI: 10.1021/BI702432Y [retrieved on 2008-02-23] the whole document	1-40

2

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2013/059145

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2005111068 A2	24-11-2005	US 2005261479 A1	24-11-2005
		WO 2005111068 A2	24-11-2005
WO 2012055854 A1	03-05-2012	AU 2011322657 A1	02-05-2013
		CA 2815267 A1	03-05-2012
		WO 2012055854 A1	03-05-2012